

ASCP | TABLE OF CONTENTS



Page 3	Letter from the ASCP President
Page 8	Hotel Map
Page 9	Award Winners
Page 14	Featured Speakers
Page 31	Acknowledgements
Page 37	Meeting Announcements
Page 44	Education Grants and Save the Date
Page 45	Sponsors
Page 46	Schedule at a Glance
Page 49	Tuesday, May 27, 2025
Page 57	Wednesday, May 28, 2025
Page 61	Thursday, May 29, 2025
Page 68	Friday, May 30, 2025
Page 71	Wednesday Posters
Page 83	Thursday Posters

"DISCLOSURES FOR ALL ASCP PRESENTERS CAN BE VIEWED AT HTTPS://ASCP.ORG/ASCP-MEETINGS/ASCP-ANNUAL-MEETING/"





Dear friends and colleagues,

It is my great honor to welcome everyone to the annual meeting of the ASCP in Scottsdale, Arizona, themed "Navigating the Evolution of Clinical Psychiatry: When Is Newer Better?" Here is the chance to consider modern perspectives about lithium and other cornerstone therapeutic agents alongside the emerging role of psychedelics, neuromodulation, novel pharmacological targets within the

glutamatergic, muscarinic, opiate and other systems, as well as advances in machine learning and precision psychopharmacology.

I want to thank our outstanding Program Committee for the Annual Meeting, led by Drs. Mark Rapaport, Tiffany Farchione, Manish Jha and Carlos Blanco, as well as the Review Subcommittee, for their tireless work in vetting an extraordinary number of submitted panels, workshops and related programs. Their coordinating efforts are especially appreciated at a time of unprecedented challenges facing our scientific community and uncertainties about the future and scope of federally supported clinical research and infrastructure.

Highlights of our meeting will include Dr. Joshua Gordon's keynote plenary session critically discussing "old versus new" pharmacotherapeutics. We are excited to honor Dr. John Kane, the winner of this year's Donald Klein Lifetime Achievement Award, and are thrilled that Dr. Stephen Stahl will present a lecture Wednesday morning on "Teaching the Teachers of Psychopharmacology" as the inaugural awardee of the new Henry Nasrallah

Award for Excellence in Psychopharmacology Education, made possible by a generous endowment to ASCP by Dr. Nasrallah. We once again have an outstanding group of new investigator awardees who will showcase their research efforts throughout the meeting. Early- and mid-career attendees will want to attend Tuesday's luncheon hosted by the Early Career Committee focusing on the peer review and publication process, as well as an afternoon interactive workshop on navigating research career trajectories. Following Wednesday's ASCP reception, our immediate-past president Dr. Les Citrome and yours truly will present a satellite CME dinner symposium on new strategies to modulate dopamine dysfunction in schizophrenia. Our robust program also includes new information about rapid-onset treatments for depression, the pharmacological management of suicidality, diagnostic conundrums, and targeting cognition in serious mental illnesses. All educators among us will want to attend Drs. Matthew Macaluso's and Richard Shelton's Thursday workshop showcasing the gargantuan efforts by their task force on the just-completed first phase of ASCP's all-new model psychopharmacology curriculum. Finally, don't miss Thursday's interactive workshop by the ASCP Presidential Task Force on the Deprescribing of Psychotropic Medications, whose members will present findings and recommendations from its large international expert panel.

A special thanks to our sponsors, both old and new, who have generously supported our meeting, as well as to our friends at the Parthenon Management Group who have worked so diligently to help plan this meeting and assure its success. Lastly, please extend a warm welcome to our incoming new president, Dr. Anita Clayton, and our new president-elect Dr. Carlos Zarate, who together I know will continue to lead and grow our organization in its scientific, educational, and clinically focused mission to improve the lives of our patients.

Enjoy the meeting!

Joseph F. Goldberg, M.D.

President

American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Program Committee for the Annual Meeting and Review Sub-Committee, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2025 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

2025 Program Highlights

- Tuesday, May 27th:
 - Meeting Opening
 - Early Career Luncheon (RSVP Only)
 - Pharmaceutical Pipeline
- Wednesday, May 28th:
 - 26th Annual Fun Run/Walk
 - Henry Nasrallah Awardee: Stephen Stahl: Teaching the Teachers of Psychopharmacology: Where Should the Focus be, on the Content, on the Presenter or on the Participant?
 - ASCP Lifetime Awardee Talk by Dr. John Kane: The Evolution of My Research in the Treatment of Schizophrenia and Unanswered Ouestions
 - Poster Session I
 - Clinical Updates in Neurotherapeutics
 - Individual Research Reports
 - ASCP Reception
 - Satellite Symposium: Schizophrenia: What's New About Dopamine and How It Is Regulated?
- Thursday, May 29th:
 - Keynote Plenary: The New and the Old of is Newer Better
 - Update From Federal and Other Funding Agencies Plus Plenary
 - Poster Session II
 - Plenary Panel: GLP-1 Agonists and Neuropsychiatric Disorders

- **o** The New Investigator Program
 - A closed workshop for 20 New Investigators and informal breakfast sessions
- Workshops: 2-hour intensive interactive sessions focused on problems and solutions on Tuesday afternoon
- * Clinical Track Sessions focused on topics of immediate clinical relevance
- ~ **Not Accredited** Per the new ACCME guidelines, these sessions cannot be accredited
- # Child/Adolescent Track Sessions focused on topics of child and adolescent relevance
- ^ **Academic Track** Sessions focused on topics of academic relevance
- + **DEI Track** Sessions focused on topics of DEI relevance

Organization

- The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
 - The Program Committee for the Annual Meeting (PCAN) organizes the meeting.
 - The Review Sub-Committee evaluates submitted proposals and develops program innovations.
- o Federal Agency & Other Funding Agency collaborations:
 - NIAAA National Institute on Alcohol Abuse and Alcoholism
 - NIDA National Institute of Drug Abuse
 - PCORI Patient-Centered Outcomes Research Institute
 - VA Veterans Administration
 - DHA Defense Health Agency
- o Society collaboration:
 - American Foundation for Suicide Prevention (AFSP)
- o Parthenon Management Group organizes the ASCP Annual Meeting.

And Remember

- The Fun Run/Walk is Wednesday, May 28th at 6:30 a.m. All are welcome to join!
- o The ASCP Reception is Wednesday, May 28th from 6:00 p.m. − 7:00 p.m. All are welcome to join!

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

11 12 cetabat in

Mark Rapaport, M.D. PCAN Co-Chair

Tiffany Farchione, M.D. PCAN Co-Chair


Manish Jha, M.D. Review Sub-Committee Co-Chair

Carlos Blanco, M.D. Review Sub-Committee Co-Chair

ASCP | HOTEL MAP




Fairmont Scottsdale Princess





Recipient of the Donald Klein Lifetime Achievement Award



John Kane, M.D.

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

John Kane, MD served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years and Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine for 12 years. He is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Co-Director of the

Institute for Behavioral Science at the Feinstein Institutes for Medical Research.

He earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA's Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, and The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society.

He has been a principal investigator on 24 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 925 peer-reviewed papers and has been consistently ranked by



Thomson Reuters in the top 1% of researchers in his field, based on citations of his work. Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.

The evolution of my research in the treatment of schizophrenia and unanswered questions.

Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award



Maggie Sibley, Ph.D.
University of Washington School of Medicine

Characteristics and predictors of fluctuating attention-deficit/hyperactivity disorder in the Multimodal Treatment of ADHD (MTA) study

Dr. Margaret Sibley is a Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine and a clinical psychologist at Seattle Children's Hospital. She has authored over 120 scholarly publications on

ADHD in adolescence and adulthood with research funded by the National Institute of Mental Health and the Institute of Education Sciences. She is Secretary of the American Professional Society for ADHD and Related Disorders (APSARD), a Professional Advisory Board Member for Children and Adults with Attention Deficit Hyperactivity Disorder (CHADD), and an Associate Editor of the Journal of Attention Disorders. She is the author of Parent-Teen Therapy for Executive Function Deficits and ADHD: Building Skills and Motivation published by Guilford Press in 2017.



Recipient of the Henry Nasrallah Award



Stephen Stahl, M.D., Ph.D., D.Sc. (Hon)., D.Med.Sci. (Hon. Cambridge)
University of California Riverside,
University of California San Diego,
University of Cambridge

Dr. Stahl is Distinguished Health Sciences Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, Adjunct Professor of Psychiatry at the University of California San Diego, Honorary Fellow in Psychiatry at the University of Cambridge and Senior

Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals. He is editor emeritus of CNS Spectrums, author of >600 articles, and over 90 textbooks including the best-selling and award winning textbook, Stahl's Essential Psychopharmacology, now in its fifth edition, and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber's Guide, now in its eighth edition. Dr. Stahl has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education, the A.E. Bennett Award of the Society of Biological Psychiatry, the Aristotle Gold Medal from Greece, the lifetime achievement award in psychiatry from the Sapienza University of Rome, the Paykel Lecture from Cambridge University, the 2013 Distinguished Psychiatrist Award of the American Psychiatric Association (APA), the 2016 David Mrazek Award Winner of the APA, in 2018 an Honorary Doctorate of Science by Üsküdar University in Istanbul Turkey and in 2024 an honorary doctorate (Doctor of Medical Sciences honoris causa) from the University of Cambridge.



2024-2025 ASCP Nina Schooler Early Career Research Awardee



Brian Sweis, M.D., Ph.D.Icahn School of Medicine at Mount Sinai

Research Title: Developing a Neuroeconomically Informed and Biologically Constrained Regret Inventory

Dr. Brian Sweis is an Assistant Professor in the Departments of Psychiatry and Neuroscience. He completed his BS/BA at Loyola University Chicago (2008-2012), MD/PhD training in neuroscience at the

University of Minnesota Medical School's Medical Scientist Training Program (2012-2020), and psychiatry residency training on the physician-scientist research track at Mount Sinai in 2020-2024 and as Chief Resident from 2023-2024. Dr. Sweis is PI of the Sweis lab, applying principles in neuroeconomics in combination with neuromodulation techniques translated across species to study complex decision-making changes in psychiatric disorders. He also serves as Director of Neuroeconomics within the Centers for Computational Psychiatry and Affective Neuroscience, as well as an Assistant Training Director for Research in the Psychiatry Residency Program to help accelerate the path toward independence for physician-scientists.



New Investigator Awardees

Alexandra Aaronson, M.D., M.Sc.

Edward Hines VA Hospital

Keren Bachi, Ph.D.

Icahn School of Medicine at Mount Sinai

Q Yosef Berlow, M.D., Ph.D.

Alpert Medical School, Brown University

Hannah Campbell, M.D., Ph.D.

Duke University

Ahmet Ceceli, Ph.D.

Icahn School of Medicine at Mount Sinai

H. Nur Eken, M.D.

University of Pittsburgh Medical Center

Danica Johnson, B.Sc.

University of Toronto

Gregory Jones, M.D.

National Institute of Mental Health

Erica Kaczmarek, B.Sc.

University of Toronto

Helena Kim, FRCPC, M.D., Ph.D. Centre for Addiction and Mental Health, University of Toronto

Nidhi Kulkarni, Ph.D.

Centre for Addiction and Mental Health

Samika Kumar, Ph.D.

National Institute of Mental Health, NIH

David Liebers, M.D.

New York University School of Medicine

William Meyerson, M.D., Ph.D.

Massachusetts General Hospital

Ynhi Thomas, M.D., M.P.H.,

Center for Innovations in Quality, Effectiveness, and Safety (IQuESt),

Andrew van der Vaart, M.D.

Sheppard Pratt Health System and University of Maryland School of Medicine

Dionne Williams, Ph.D.

Janssen Pharmaceuticals and Drexel University

Kengo Yonezawa, M.D.

Keio University School of Medicine



Henry Nasrallah Awardee: Stephen Stahl Wednesday, May 28th: 8:30 a.m. – 10:00 a.m.



Stephen Stahl, M.D., Ph.D., D.Sc. (Hon)., D.Med.Sci. (Hon. Cambridge)
University of California Riverside,
University of California San Diego,
University of Cambridge

Dr. Stahl is Distinguished Health Sciences Clinical Professor of Psychiatry and Neuroscience at the University of California Riverside, Adjunct Professor of Psychiatry at the University of California San Diego, Honorary Fellow in Psychiatry

at the University of Cambridge and Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals. He is editor emeritus of CNS Spectrums, author of >600 articles, and over 90 textbooks including the best-selling and award winning textbook, Stahl's Essential Psychopharmacology, now in its fifth edition, and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber's Guide, now in its eighth edition. Dr. Stahl has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education, the A.E. Bennett Award of the Society of Biological Psychiatry, the Aristotle Gold Medal from Greece, the lifetime achievement award in psychiatry from the Sapienza University of Rome, the Paykel Lecture from Cambridge University, the 2013 Distinguished Psychiatrist Award of the American Psychiatric Association (APA), the 2016 David Mrazek Award Winner of the APA, in 2018 an Honorary Doctorate of Science by Üsküdar University in Istanbul Turkey and in 2024 an honorary doctorate (Doctor of Medical Sciences honoris causa) from the University of Cambridge.



<u>Clinical Updates in Neurotherapeutics</u> Wednesday, May 28th: 1:00 p.m. – 2:30 p.m.



Noah Philip, M.D. Alpert Medical School of Brown University

Dr. Philip is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. His clinical and laboratory work is at the Veterans Hospital in Providence Rhode Island USA, where he is the Lead for Mental Health Research at the Center for Neurorestoration and Neurotechnology and founding director of the psychiatric neuromodulation clinic at VA Providence.

Dr. Philip received his BSc from McGill University, and his MD from Albany Medical College where he graduated Alpha Omega Alpha and with a Distinction in the Study of Biomedical Ethics. He then completed his psychiatry residency training at Brown, followed by T32 and Neuromodulation Fellowships also at Brown under the mentorship of Drs. Lawrence H Price and Linda L Carpenter.

Dr. Philip's laboratory uses a precision approach to new and emerging technologies, with the goal to understand and treat posttraumatic stress disorder, major depression, and suicidality. His research has been featured in JAMA Psychiatry, American Journal of Psychiatry, Biological Psychiatry, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). He is currently conducting an NIMH-funded cooperative study to perform a first-in-human study investigating MRI-guided low intensity focused ultrasound for depression and anxiety (U01 MH123427).



Dr. Philip plays a significant training and mentoring role at Brown, where he is Associate Director of the NIMH R25 psychiatry resident research training program, and serves as a mentor through several national organizations. He is committed to action to improve diversity, equity, inclusion, and belonging.



Joan Camprodon, M.D., M.P.H., Ph.D.

Massachusetts General Hospital,

Harvard Medical School

Dr. Joan Camprodon is the inaugural chief of the Division of Neuropsychiatry and Neuromodulation at Massachusetts General Hospital and Associate Professor of Psychiatry and Neurology at Harvard Medical School. Clinically, he is the

founding director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee, and an attending physician in the departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in Psychiatry and Behavioral Neurology-Neuropsychiatry.

Scientifically, he directs the Laboratory for Circuit Neuroscience and Neuromodulation. His research uses multimodal combinations of brain stimulation, neuroimaging, neurophysiology, and behavioral methods to investigate neural circuitry and plasticity in a translational manner. The scope of his research includes basic, translational, and clinical projects focused on human circuit neuroscience. Projects in his laboratory address (1) the anatomy, physiology, and behavioral computations of disease-relevant networks, (2) circuit-level pathophysiological mechanisms (with



an emphasis on transdiagnostic processes and the role of plasticity), and (3) the translational development of tools to support clinical care and decision-making (e.g., biomarker discovery and treatment development). Critical efforts are geared towards applying the paradigms and methods of human systems/cognitive neuroscience to discover treatment targets that support the development of individualized precision therapeutics.



Charles Conway, M.D.Washington University in St. Louis

Dr. Charles R. Conway is a Professor of Psychiatry and clinician-researcher at Washington University School of Medicine. His research focus is mood disorders, specifically in treatment-resistant major depression (TRMD), a virulent form of major depressive disorder (MDD) which fails to respond to numerous standard treatments. His primary research focus is to better understand the biological and neurophysiological basis of TRMD using

neuroimaging, genetics, inflammatory measures, and other biological markers. Further, using this understanding, to develop novel treatment alternatives to improve clinical outcomes and decrease poor outcomes.

Currently, Dr. Conway serves as the Director of the Washington University Treatment-Resistant Mood Disorders Center, which takes referrals from psychiatrists nationwide to provide evaluation and treatment recommendations for individuals with this severe form of depression. Additionally, the center maintains a large database of over 170 TRMD patients seen in the past 15 years, in part to examine associated factors or predictors of disease including family/treatment history, age of onset, history of trauma, personality structure, and response to future treatments (among others).



Throughout the past 25 years, Dr. Conway has been critically involved in the development, management, and successful completion of multiple challenging TRMD research projects. A significant part of this work has focused on how vagus nerve stimulation (VNS), a permanent implantable device, produces antidepressant effects. Dr. Conway is serving as the lead investigator for the RECOVER vagus nerve stimulation trial, the largest, device-based TRMD trial ever conducted. Additionally, his group has been a national leader in the development of inhaled nitrous oxide (an inhaled NMDA-antagonist) in the treatment of TRMD.



Scott Aaronson, M.D. Sheppard Pratt

Scott T. Aaronson, MD, is Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt Health System in Baltimore, Maryland, where he has been responsible for developing a research program dedicated to the development of medications and devices devoted towards alleviating

the burden of severe psychiatric illness across the spectrum of psychiatric disorders. He is Principal Investigator for studies in various phases and presentations of affective illness and anxiety disorders. Most of his work in recent years has been related to the use of neurostimulation modalities such as Transcranial Magnetic Stimulation and Vagus Nerve Stimulation and the use of psychedelic assisted therapy. His recent studies include first clinical experience of the use of psychedelics in bipolar type II depression and in chronic active suicidal depression.

Dr. Aaronson earned his medical degree with honors from Harvard Medical School in Boston and completed a residency in Psychiatry at McLean Hospital in Belmont, Massachusetts. He is an Adjunct Professor



of Psychiatry at the University of Maryland, School of Medicine, a Distinguished Life Fellow in the American Psychiatric Association and a Fellow of the American College of Psychiatrists, the Clinical TMS Society and the American Society for Clinical Psychopharmacology. He currently serves on the Board of the American Society for Clinical Psychopharmacology.

Keynote Plenary: Thursday, May 29th: 8:15 a.m. - 9:15 a.m.



Joshua Gordon, M.D. Columbia University

Dr. Gordon earned his MD and PhD from the University of California, San Francisco. He previously served on the Columbia faculty before becoming the Director of the National Institute of Mental Health in 2016. Dr. Gordon returned to Columbia this year to serve as Chair of the Department of Psychiatry, Executive Director of the New York State Psychiatric Institute, and Psychiatrist-in-Chief

at New York-Presbyterian Hospital-Columbia University Irving Medical Center.



<u>Update from Federal and Other Funding Agencies Plus</u> Thursday, May 29th: 9:30 a.m. – 11:30 a.m.



Joseph Goldberg, M.D.
Icahn School of Medicine at Mount Sinai

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. Educated at the University of Chicago and Northwestern University Medical School, he completed his psychiatry training and psychopharmacology research fellowship at the Payne Whitney Clinic, New York Presbyterian Hospital. He has published over 220 peer-reviewed papers on psychopharmacology and mood disorders, as

well as four books, most recently "Practical Psychopharmacology: Translating Findings From Evidence-Based Trials into Real-World Clinical Practice" published in 2021 by Cambridge University Press. He has served on the Board of Directors for the American Society of Clinical Psychopharmacology and is an Editor for the Journal of Clinical Psychiatry. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly's "America's Top Doctor."





Ivan Montoya, M.D., M.P.H.DHHS/National Institute on Drug Abuse

Dr. Montoya is the Director of the Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA), which is one the institutes of the National Institutes of Health (NIH). He has a Medical Doctor and Psychiatrist degrees from the University of Antioquia in

Colombia, and a Master's in Public Health from Johns Hopkins University. He was a Fulbright-Humphrey Fellow at Johns Hopkins and Visiting Fellow at the Intramural Research Program 5 2024 ASCP Annual Meeting of NIDA. He joined NIDA's extramural program in 1999 as Medical Officer of the Clinical Trials Network, became the Deputy Director of DTMC in 2008 and the Director of DTMC in 2024. He has published extensively about treatments (pharmacological and non-pharmacological), and medical consequences of SUDs. He has received multiple awards including the NIH Director's Award and the Michael Morrison Award from CPDD. He is also Honorary Professor of the University of Valencia (Spain).





Daniel Falk, Ph.D. NIAAA/NIH

Dr. Daniel Falk is the Branch Chief of the Medications Development Branch (MDB) within the Division of Treatment and Recovery (DTR) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). At NIAAA, he directs research on pharmacotherapy for alcohol use disorder (AUD) and novel methods for clinical trials, including the evaluation of new endpoints. Dr. Falk co-leads the

NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP) - a contract program which evaluates the efficacy and safety of novel and repurposed compounds to treat AUD in laboratory and randomized clinical trials. Dr. Falk is also the Coordinator of the NIAAA Data Archive, a large data repository over 400 NIAAA funded studies involving human subjects. Dr. Falk has authored a number of publications and presentations on a diverse set of alcohol-related topics, including pharmacotherapy to treat AUD, statistical methods and outcomes for alcohol clinical trials, psychiatric comorbidity of AUD, and correlates of alcohol use. Prior to joining NIAAA, he conducted epidemiologic research on AUD as a contractor for NIAAA. Dr. Falk received his Ph.D. in Clinical Psychology from the University of Miami.





Lori Davis, M.D. Veterans Affairs Medical Center

Lori Davis, M.D., has been a VA clinical researcher for the past 30 years and has held continuous peer-review funding with a predominance of VA awards. She has been asked to deliver this talk on behalf of the VA Office of Research and Development central office leadership.is also Honorary Professor of the University of Valencia (Spain).



Fuad Issa, M.D.Defense Health Agency

Dr. Issa has been active in clinical research for 35 years. Since January 2022 he has been the Psychological Health Research Portfolio Manager at Research & Engineering Directorate, Defense Health Agency (DHA). Prior to that Dr. Issa served as Chief of Clinical Care at DHA Psychological Health Center of Excellence since 2016. He has worked in the civilian, military and veteran mental health arenas both in clinical and

research capacities. Dr. Issa has published in peer-reviewed journals, presented at national and international conferences, and authored book 10 2024 ASCP Annual Meeting chapters. Dr. Issa is board certified in Psychiatry, distinguished life fellow of the American Psychiatric Association, member of Society of Biological Psychiatry and American Medical Association. He is a Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University.





Yu-Ping (Tracy) Wang, M.D., M.Sc. Patient-Centered Outcomes Research Institute (PCORI)

Tracy Y. Wang, MD, MHS, MSc, is Chief of Comparative Clinical Effectiveness Research at the Patient-Centered Outcomes Research Institute (PCORI). She is a cardiologist and clinical researcher with expertise in observational research, implementation science, and pragmatic randomized clinical trials.

Wang leads PCORI's comparative effectiveness research portfolio focused on increasing the evidence base for existing interventions and emerging innovations to improve health outcomes and health equity through multidisciplinary research. She provides strategic guidance and oversight of ongoing programs and new initiatives designed to enhance and accelerate patient-centered comparative effectiveness research. Prior to her current role, Wang was Professor of Medicine at Duke University and led several large studies at the Duke Clinical Research Institute that have focused on comparative effectiveness and safety, health disparities, care quality assessment, and quality improvement. To date, she has published over 350 peer-reviewed manuscripts, lectured widely on pragmatic trials and the use of data to guide initiatives aimed at reducing disparities in healthcare access and outcomes. Additionally, she has evolved the platform for research to diversify site and patient recruitment, innovate longitudinal patient follow-up, enrich the collection of patientreported outcomes, and pragmatically adjudicate clinical events of interest. She previously served as Assistant Dean of Continuing Medical Education and Director of Health Services and Outcomes Research at Duke. Wang has served on numerous volunteer committees, tasks forces, and writing groups for the American Heart Association, American College of



Cardiology, and American College of Physicians. She previously chaired the AHA Council Operations Committee (2020-22) and AHA's Quality of Care and Outcomes Research (QCOR) Council (2017-19). She is an Associate Editor of the JAMA Internal Medicine journal and serves on the editorial boards of several other high-impact journals. In 2022, she was awarded the American Heart Association QCOR Outstanding Lifetime Achievement Award, and has received multiple awards recognizing her excellence in mentorship and leadership in enhancing diversity in both research participants and workforce.

An undergraduate of Yale University, Wang received her MD from Harvard Medical School, MSc in molecular biochemistry and biophysics from Yale University, and MHS in clinical research from Duke University.



Anita Clayton, M.D. University of Virginia

Dr. Anita Clayton's clinical practice and research interests focus on women's mental health and sexual dysfunctions. She is the David C. Wilson Professor and Chair of the Department of Psychiatry and Neurobehavioral Sciences, with a secondary appointment as professor of clinical obstetrics and gynecology. She is board certified in psychiatry and neurology.

Dr. Clayton was born in Pensacola, FL, where her father was stationed as a Navy pilot; she grew up traveling throughout the world for her father's assignments. She finished high school in Virginia Beach and then attended the University of Virginia for her undergraduate and medical degrees. She also completed her internship and residency in behavioral medicine and



psychiatry at UVA. Dr. Clayton then served as a U.S. Navy physician for four years before returning to join the faculty at UVA in 1990.

Married for 34 years, Dr. Clayton has a son, a daughter and three stepsons. She enjoys traveling and the arts.



Mark Rapaport, M.D.
University of Utah Huntsman Mental Health
Institute

Mark Hyman Rapaport, MD, Professor, joined the University of Utah in January 2021 as Chairman of the Department of Psychiatry and inaugural CEO of the Huntsman Mental Health Institute (HMHI), a role he held until February 2025. He also served as the second William H. and Edna D. Stimson Presidential Endowed Chair at the Spencer Fox Eccles School of Medicine and as Founding CEO, Emeritus, of

HMHI.

During his tenure, Dr. Rapaport led numerous initiatives, including the construction of the Kem and Carolyn Gardner Mental Health Crisis Care Center, the Utah Mental Health Translational Research Building, and the "Love, Your Mind" public awareness campaign with the Ad Council. He also spearheaded the Stop Stigma Together movement, the Utah School Mental Health Collaborative, and expanded mental health services.

From 2011 to 2020, Dr. Rapaport was Chairman at Emory University's Department of Psychiatry and Behavioral Sciences and Chief of Psychiatric Services at Emory Healthcare. He also served at Cedars-Sinai Medical Center and the University of California, San Diego. Dr. Rapaport has been involved with various NIH committees and received funding



from NIMH, NIDA, and other organizations for his research in psychoneuroimmunology, psychopharmacology, and clinical trial methodology.

He has authored over 200 articles in peer-reviewed journals and is currently Editor of Focus: The Journal of Lifelong Learning in Psychiatry. Dr. Rapaport is a distinguished fellow of the American Psychiatric Association and the Collegium International Neuropsychopharmacology. He is board certified in Psychiatry since 1987.

Plenary Panel: GLP-1 Agonists and Neuropsychiatric Disorders Thursday, May 29th: 4:30 p.m. – 6:30 p.m.



Nigel Greig, Ph.D.National Institute on Aging, NIH

Nigel Greig was trained as a pharmacologist with a background in medicinal chemistry and physiology, and gained his Ph.D. from the University of London (Department of Pharmacology, Royal College of Surgeons, England). The research portion of his Ph.D. was undertaken within the Cancer Chemotherapy Department of the Imperial

Cancer Research Fund (ICRF) under the mentorship of Prof. Kurt Hellmann – who took the drugs razoxane and dexrazoxane (Zinecard, Cardioxane) from concept to the clinic.

Leaving the ICRF and Britain in 1982, Nigel joined the Laboratory of Neuroscience within the Intramural Research Program (IRP), National Institute on Aging (NIA), National Institutes of Health (NIH), as a Postdoc in the US. His initial studies focused on optimizing the delivery to and



action of drugs within the brain. This resulted in the development of drug candidates for the treatment of brain tumors and cancers of the breast, lymphatics and ovaries, as well as technology for the brain delivery of neuropeptides, antisense oligonucleotides and proteins. Leaving NIA in 1989, Nigel was one of the initial scientists in the California-based Alzheimer biotechnology company, Athena Neurosciences, which later became a key part of Elan Pharmaceuticals and is now part of Perrigo. Athena was launched on technology deriving from Nigel's NIA research as well as separate technology from the Selkoe Laboratory, Harvard University.

Returning to NIA as a tenured scientist in 1992, Nigel's research has evolved into his present focus, the design and development of drugs for the treatment of degenerative disorders prevalent in aging, with particular emphasis on chronic (Alzheimer's and Parkinson's disease) and acute (traumatic brain injury and ischemic stroke) neurodegenerative disorders, and type 2 diabetes. He heads the Drug Design & Development Section within the Translational Gerontology Branch, IRP, NIA, NIH, located in Baltimore, MD, USA.

Nigel's program combines cellular and in vivo pharmacology and neurobiology with medicinal chemistry to design and develop novel experimental drugs against rate-limiting steps involved in the pathophysiology of diseases associated with aging. In extensive studies with a core of long-time, close collaborators from academia within and outside the US, Pharma and NIH - together - they have successfully moved multiple experimental drugs from concept through preclinical studies and into human clinical trials (Phenserine, Posiphen (Buntanetap, ANVS 405), Bisnorcymserine (ANVS 301), Exendin-4 (Exenatide, PT320)). These, as well as new preclinical drugs, have been licensed from NIA, NIH, and collaborating institutions into both new startup as well as



existing companies to support their clinical development to improve public health.



Christian Hendershot, Ph.D. Keck School of Medicine

Dr. Hendershot is Professor at the Keck School of Medicine, University of Southern California, and Director of Clinical Research at the USC Institute for Addiction Science. His research uses human pharmacology and clinical trial methods to study the etiology and treatment of substance use disorders. Dr. Hendershot has recently led some of the earliest Phase

II trials investigating the efficacy of long-acting GLP-1 receptor agonists in participants with tobacco use disorder and alcohol use disorder.



Mahavir Agarwal, M.D., Ph.D. University of Toronto

Dr. Mahavir Agarwal MBBS, MD, PhD is an Associate Professor in the Department of Psychiatry at the University of Toronto and a Clinician-Scientist in the Schizophrenia Division at the Centre for Addiction at Mental Health (CAMH), Toronto. He is also the Medical Head for Clinical Research in the Schizophrenia Division and leads the Metabolic Clinic and the Clozapine Clinic at CAMH.



Dr. Agarwal's research interest lies in understanding the mechanisms underlying metabolic and cognitive dysfunction in severe mental illness and in discovering new treatments for these abnormalities. He has won several international research awards and his research program has been funded by several federal and provincial agencies including the Canadian Institutes of Health Research (CIHR), PSI Foundation, CAMH, and the University of Toronto.



Rodrigo Mansur, M.D., Ph.D. University Health Network

Dr. Mansur is a staff psychiatrist at the University Health Network (UHN) in Toronto and an Associate Professor in the Department of Psychiatry at the University of Toronto. Dr. Mansur completed his medical degree at the Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), Brazil. He received his Psychiatry residency training and PhD at

UNIFESP/EPM; and Fellowship training in Psychiatry at the University of Toronto. Dr. Mansur's research has focused primarily on investigations of etiological processes of mood disorders, using a combination of clinical and neurobiological methods, and the development and evaluation of mechanistically novel interventions for these conditions. Current targets of interest include the role of brain insulin signaling, which his team has explored using innovative approaches, such as functional magnetic resonance imaging and modern biomarkers techniques. Dr. Mansur also leads a clinical trials unit, designing and executing studies testing the potential of anti-diabetes and weight loss agents in the treatment of depression and bipolar disorder.



Program Committee for the Annual Meeting (PCAN) Chairs



Mark H. Rapaport, M.D.



Tiffany Farchione, M.D.

Review Sub-Committee Chairs



Carlos Blanco, M.D.



Manish Jha, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Ivan Montoya, M.D., Ph.D.



<u>Program Committee for the Annual Meeting and Review Sub-</u> <u>Committee Members</u>

Scott Aaronson, M.D. * Sheppard Pratt

Saeed Ahmed, M.D. Saint Francis Hospital and Medical Center, Trinity Health of New England

Raman Baweja, M.D. Penn State College of Medicine

Carlos Blanco, M.D. National Institute on Drug Abuse

★ Cherise Chin Fatt, Ph.D. Center for Depression Research and Clinical Care, UTSW

Leslie Citrome, M.D., M.P.H. New York Medical College

Lawrence Cohen, B.A., Pharm.D. UNT System College of Pharmacy/ Regulatory Insurance Advisors

M. Crismon, Pharm.D.
The University of Texas at
Austin

Justin Faden, D.O. Temple University ★ Tiffany Farchione, M.D. US Food and Drug Administration

Marlene Freeman, M.D. Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

Ahmad Hameed, M.D. Penn State College of Medicine

★ Rebecca Hendrickson, M.D., Ph.D. VA Puget Sound Health Care System

Michael Henry, M.D. Massachusetts General Hospital

★ Dan Iosifescu, M.D., M.Sc. New York University School of Medicine

★ Manish Jha, M.D. University of Texas Southwestern Medical Center

★ Shixie Jiang, M.D. University of Florida, College of Medicine



★ Jordan Karp, M.D.
University of Arizona College of
Medicine

Susan Kornstein, M.D. Virginia Commonwealth University

Valentina Mantua, M.D. Center for Drug Evaluation and Research, Food and Drug Administration

- ★ Matej Markota, M.D. Mayo Clinic
- ★ Nicholas Murphy, Ph.D. Baylor College of Medicine
- ★ Carla Nasca, Ph.D.

 NYU Langone Department of Psychiatry

Andrew Nierenberg, M.D. Massachusetts General Hospital

Luca Pani, M.D. * University of Miami

Mark Rapaport, M.D. University of Utah Huntsman Mental Health Institute Gerard Sanacora, M.D., Ph.D. Yale

- ★ Manpreet Singh, M.D., M.S. University of California, Davis, School of Medicine
- ★ Jair Soares, M.D., Ph.D. University of Texas School of Medicine at Houston

Louisa Steinberg, M.D. ICON Plc

Oleg Tcheremissine, M.D. Atrium Health

Antonio Teixeira, M.D. University of Texas Health Science Center at San Antonio

Ottavio Vitolo, M.D. Cerevance

Eric Wexler, M.D., Ph.D. Modernbrains

- ★ Carlos Zarate, M.D. National Institute of Mental Health
- ★ Zachary Zuschlag, D.O. James A. Haley Veterans Hospital



New Investigator Award Program Committee

- ★ Mahavir Agarwal, M.D., Ph.D. Centre for Addiction and Mental Health (CAMH), Canada
- ★ Elizabeth Ballard, Ph.D. National Institute of Mental Health
- ★ Lori Davis, M.D. Veterans Affairs Medical Center
- ★ Walter Dunn, M.D., Ph.D. West Los Angeles VA Medical Center/UCLA
- ★ Tiffany Farchione, M.D. US Food and Drug Administration

Margaret Grabb, Ph.D. National Institute of Mental Health Bruce Kinon, M.D. MycoMedica Life Sciences

Ivan Montoya, M.D., M.P.H. DHHS/National Institute on Drug Abuse

★ Katharine Phillips, M.D. Weill Cornell Medical College and New York-Presbyterian/Weill Cornell Medical Center

Mark Rapaport, M.D. University of Utah Huntsman Mental Health Institute

Nina Schooler, Ph.D. SUNY Downstate Health Sciences Center

★ Holly Swartz, M.D. University of Pittsburgh School of Medicine



ASCP Officers and Board

- ★ Joseph F. Goldberg, M.D. *
 President
 Icahn School of Medicine at
 Mount Sinai
- ★ Anita H. Clayton, M.D. President Elect University of Virginia

Leslie Citrome, M.D.
Past President
New York Medical College

- ★ Holly Swartz, M.D.

 Treasurer

 University of Pittsburgh School of Medicine
- ★ Dan Iosifescu, M.D. Treasurer Elect New York University School of Medicine

Trisha Suppes, M.D., Ph.D. Past Treasurer Stanford University

Scott Aaronson, M.D. * Sheppard Pratt

- Alexandra Aaronson, M.D., M.Sc.
 Edward Hines VA Hospital
- ★ Mahavir Agarwal, M.D., Ph.D. Centre for Addiction and Mental Health (CAMH)
- ★ Crystal Clark, M.D. *
 University of Toronto, Women's
 College Hospital
- ★ Christoph Correll, M.D. The Zucker Hillside Hospital

Marlene Freeman, M.D. Editor of the *Journal of Clinical Psychiatry* Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

Susan Kornstein, M.D. Virginia Commonwealth University

Matthew Macaluso, D.O. The University of Alabama at Birmingham Stephen Marder, M.D. Semel Institute at UCLA

Sanjay Matthew, M.D. Baylor College of Medicine

★ George Papakostas, M.D. Massachusetts General Hospital Gerard Sanacora, M.D., Ph.D.Yale

★ Erika Saunders, M.D.
Penn State College of Medicine,
Penn State Health

★ Carlos Zarate, M.D. National Institute of Mental Health

★New Investigator Alumni *Representing ASCP CME Committee

ASCP | MEETING ANNOUNCEMENTS



Registration Desk* Hours:

 $\begin{array}{lll} \mbox{Monday} & 1:00 \ \mbox{p.m.} - 5:00 \ \mbox{p.m.} \\ \mbox{Tuesday} & 7:30 \ \mbox{a.m.} - 6:00 \ \mbox{p.m.} \\ \mbox{Wednesday} & 7:30 \ \mbox{a.m.} - 7:00 \ \mbox{p.m.} \\ \mbox{Thursday} & 7:30 \ \mbox{a.m.} - 6:00 \ \mbox{p.m.} \\ \mbox{Friday} & 7:30 \ \mbox{a.m.} - 10:00 \ \mbox{a.m.} \end{array}$

Speaker Ready Room* Hours:

 Monday
 1:00 p.m. - 5:00 p.m.

 Tuesday
 7:30 a.m. - 6:00 p.m.

 Wednesday
 7:30 a.m. - 6:00 p.m.

 Thursday
 7:30 a.m. - 6:00 p.m.

 Friday
 7:30 a.m. - 10:00 a.m.

*The Speaker Ready Room is located in Bourbon 11 of the Fairmont Scottsdale Princess.

The meeting organizers ask that all speakers upload their slides no later than 24 hours prior to their scheduled presentation time.

ASCP Wi-Fi

SSID: Fairmont-Meeting Access Code: ASCP2025

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

^{*}The registration/meeting information desk is located in the Princess East Foyer of the Fairmont Scottsdale Princess.

ASCP | MEETING ANNOUNCEMENTS



Discounts – All ASCP meeting attendees who booked their room at the Fairmont Scottsdale Princess through the ASCP website will have the following resort amenities.

- Unlimited basic internet access in your guest rooms and resort public areas.
- Any local and 1-800 access calls from your guest room.
- Complimentary self-parking for one vehicle per room.
- Complimentary half-day admission to Trailblazers kid's adventure club access for up to three children.
- Access to 24-hour Fairmont Fitness Center.
- On-site shuttle transportation service (guest rooms, restaurants, spa, pool and meeting space).
- 50% discount off Well & Being Spa daily access fee including complimentary fitness and wellness classes, waterfall treatment pool, sauna, and rooftop pool.
- 10% discount off a 60-, 90- or 120-minute personal service at Well & Being Spa

ASCP Membership - If you would like to join ASCP, you can log onto our website at https://ascpp.org/ascp-meetings/ascp-annual-meeting/ and register online. Membership applications are available at the ASCP registration desk, located in the Princess East Foyer. You may also contact the ASCP office at 615-649-3085 to request one.

ASCP | MEETING ANNOUNCEMENTS



Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. Self-assessment maintenance of certification credits are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the meeting at www.ASCPMeeting.org. Surveys for continuing education credit must be submitted no later than Tuesday, July 01, 2025.

There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

The American Board of Psychiatry and Neurology has reviewed the annual meeting and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Live Continuing Education

American Society of Clinical Psychopharmacology 2025 ASCP Annual Meeting May 27 - 30, 2025 Scottsdale, AZ

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and



implemented by Amedoo LLC and American Society of Clinical Psychopharmacology. Amedoo LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses

Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of $21.00 \, AMA \, PRA \, Category \, 1 \, Credits^{TM}$ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 21.00 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurses

Amedo LLC designates this activity for a maximum of 21.00 ANCC contact hours.

Psychologists



This course is co-sponsored by Amedco and American Society of Clinical Psychopharmacology. Amedco is approved by the American Psychological Association to sponsor

continuing education for psychologists. Amedoo maintains responsibility for this program and content. Maximum of 21.00 hours.

The following state boards accept courses from APA providers for Psychologists/Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, MA (LEP ONLY), MD, ME, MN, MO, NC, ND, NH, NE, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

MI: Accepts courses from APA for Psychologists. No general CE requirement for Counselors.

OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

MI MFTs: There are no CE requirements for MFTs in MI.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK*, OR, SC, UT, WA, WI, WY

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

New York Psychologists

Amedoo is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. 21.00 hours.

Enduring Continuing Education

American Society of Clinical Psychopharmacology

2025 ASCP Annual Meeting

BMS Satellite Symposium: Schizophrenia: What's New About Dopamine and How It is Regulated

June 27, 2025 - September 27, 2025

Scottsdale, AZ

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and



implemented by Amedco LLC and American Society of Clinical Psychopharmacology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American

Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits*TM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians

Amedco LLC designates this activity for a maximum of 1.00 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurses

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Psychologists

This course is co-sponsored by Amedco and American Society of Clinical



Psychopharmacology. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this

program and content. Maximum of 1.00 hours.

The following state boards accept courses from APA providers for Psychologists/Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, MA (LEP ONLY), MD, ME, MN, MO, NC, ND, NH, NE, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY MI: Accepts courses from APA for Psychologists. No general CE requirement for Counselors.

OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY

AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

MI MFTs: There are no CE requirements for MFTs in MI.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY ONLY), OK*, OR, SC, UT, WA, WI, WY

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

New York Psychologists

Amedoo is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. 1.00 hours.

ASCP | EDUCATIONAL GRANTS



ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

Alkermes

Boehringer Ingelheim

Bristol Myers-Squibb

Intra-Cellular Therapies

Neurocrine

ASCP | SAVE THE DATE



2026 ASCP Annual Meeting

Save the Date



The 2026 ASCP Annual Meeting will take place May 26 - May 29, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida. Details regarding abstract submission for the 2026 Annual Meeting will be released in September 2025.

ASCP | Sponsorships



Thank you to our sponsors for their support.







2025 ASCP ANNUAL MEETING

Navigating the Evolution of Clinical Psychiatry: When is Newer Better



SCHEDULE AT A GLANCE

Monday, May 26

REGISTRATON 1:00PM - 5:00PM

SPEAKER READY 1:00PM - 5:00PM

8AM - 4:45 PM

MSL Preceptorship (Additional Registration Required)

Moor 1

8AM - 4:55pm

NIA Workshop (Invitation Only)
Palomino 1-3

Tuesday, May 27

REGISTRATON 7:30AM - 6PM

SPEAKER READY 7:30AM - 6PM

7:30AM-9AM

Morning Break
Princess East Foyer

8:30AM - 9:00AM

Meeting Opening
Princess Ballroom (Salon) A-E

9:00AM - 10:30 AM

Panel Sessions

- Using Group Medical Visits / Shared Medical Appointments to Improve Access to Care for Bipolar Disorder and Other Psychiatric Disorders: Evaluation of a Novel Service Delivery Model
 - Princess Ballroom (Salon) F
- Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice
 - Princess Ballroom (Salon) G
- Recent Advances in Ketamine and Esketamine: Research and Clinical Practice
 - Princess Ballroom (Salon) H
- Expanding the Reach of Clinical Trials: Including Patients with Suicidal Thoughts and Behavior
 - Princess Ballroom (Salon) I



or visit our website. Information is subject to change, so stay updated through these platforms.

Tuesday, May 27

10:30AM - 11AM

Break

11AM - 12:30PM

Panel Sessions

- Reimagining Lithium From Bedside to Bench
 - Princess Ballroom (Salon) F
- Alcohol and Cocaine Use Disorders: New Findings in Telehealth and Novel Treatment Approaches
 - Princess Ballroom (Salon) G
- Targeting Major Depressive Disorder Subtypes for Treatment Development. Selecting Optimal Assets from the Pipeline
 - Princess Ballroom (Salon) H
- Optimizing and Developing Transcranial Magnetic Stimulation in the Veterans Affairs Healthcare System: Research Updates from the National TMS Program
 - Princess Ballroom (Salon) I

12:30PM - 2PM

Early Career Luncheon (RSVP Required)
Palomino 1-3

2PM-4PM

Pharmaceutical Pipeline Session Princess Ballroom (Salon) A-E

4PM - 4:15PM

Break





2025 ASCP ANNUAL MEETING

Navigating the Evolution of Clinical Psychiatry: When is Newer Better



SCHEDULE AT A GLANCE

Tuesday, May 27

4:15PM - 6:15PM

Workshops

- Recent Results From NIMH-Funded Clinical Trials of Rapid Antidepressants to Reduce Suicide Risk
 - Princess Ballroom (Salon) F
- Navigating Research Career Trajectories: An Interactive Workshop and Toolkit for Building Teams, Nurturing Relationships, and Ethical and Inclusive Clinical Research Practice for the Long Haul
 - Princess Ballroom (Salon) G
- Evolving Pharmacotherapy Targets in Mood Disorders: When the Old Meets the New, the Tried, and the True
 - Princess Ballroom (Salon) H
- Bipolar Disorder Versus Borderline Personality Disorder: A Clinical Conundrum
 - Princess Ballroom (Salon) I

6:30PM - 8PM

New Investigator Award (NIA) Ceremony (Invitation Only)

Wednesday, May 28

REGISTRATON 7:30AM - 7PM

SPEAKER READY 7:30AM - 6PM

6:30AM - 8AM

Annual ASCP Fun Run/Walk
Palomino Conference Center North Drive

7:30AM - 9AM

Morning Break
Princess East Foyer

8:30AM - 10AM

Henry Nasrallah Awardee: Stephen Stahl Princess Ballroom (Salon) A-E

10AM - 10:15AM

Break

10:15AM - 11:15AM

ASCP Awards Ceremony and ASCP Lifetime Awardee Talk

Princess Ballroom (Salon) A-E

Wednesday, May 28

11:15AM - 1PM

Poster Session I with Lunch Palomino 4-10

11:15AM - 1PM

Early Career Networking Tables Palomino 4-10

1PM - 2:30PM

Clinical Updates in Neurotherapeutics Princess Ballroom (Salon) A-E

2:30PM - 3PM

Break

3PM - 4:30PM

Individual Research Reports

- Innovations in Novel Therapeutics for Mood, Anxiety and Related Disorders
 - Princess Ballroom (Salon) H
- Advances in Psychosis and Neurocognitive Disorders Research
 - Princess Ballroom (Salon) F
- Update on Biomarkers Research
 - Princess Ballroom (Salon) G
- Bipolar Disorder
 - Princess Ballroom (Salon) I

5PM - 6PM

ASCP Business Meeting (ASCP Members Only)
Princess Ballroom (Salon) H

6PM - 7PM

ASCP Reception Hacienda Trellis & Plaza

7:00PM - 8:30PM

Satellite Symposium

- Schizophrenia: What's New About Dopamine and How It Is Regulated? (Pre-Registration Required)
 - Palomino 1-3



2025 ASCP ANNUAL MEETING

Navigating the Evolution of Clinical Psychiatry: When is Newer Better



SCHEDULE AT A GLANCE

Thursday, May 29

REGISTRATON 7:30AM - 6PM

SPEAKER READY 7:30AM - 6PM

7:30AM - 9AM

Morning Break
Princess East Foyer

8:15AM - 9:15AM

Keynote Plenary

- The New and the Old of is Newer Better
 - Princess Ballroom (Salon) A-E

9:15AM - 9:30AM

Break

9:30AM - 11:30AM

Update from Federal and Other Funding Agencies Plus Plenary

Princess Ballroom (Salon) A-E

11:15AM - 1PM

Poster Session II with Lunch Palomino 4-10

11:15AM - 1PM

Early Career Networking Tables Palomino 4-10

1:15PM - 2:45PM

Panel Sessions/Workshops

- Can We Make Cognitive Enhancement a More Achievable Therapeutic Target in SMI Clinical Trials?
 - Princess Ballroom (Salon) F
- Novel Therapies for Individuals with Cocaine/Methamphetamine Use Disorder: Findings from Studies within the NIDA Clinical Trials Network
 - Princess Ballroom (Salon) G
- Re-Evaluating Methodologies in Psychiatric Clinical Trials: Lessons from Psychedelic Studies and Beyond
 - Princess Ballroom (Salon) H
- Practical Considerations for Deprescribing Psychiatric Medication
 - Princess Ballroom (Salon) I

3PM - 4:30PM

Panel Sessions

- Harnessing Educational Technology to Advance Education: The Next Generation ASCP Model Psychopharmacology Curriculum
 - Princess Ballroom (Salon) F
- A Healthy Mind in a Healthy Body: Findings from Translational Research into Causes, Treatments, and their Impacts
 - Princess Ballroom (Salon) G
- Bipolar Action Network: A Prototype for a Learning Health Network
 - Princess Ballroom (Salon) H
- Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding
 - Princess Ballroom (Salon) I

4:30PM - 6:30PM

Plenary Panel

- · GLP-1 Agonists and Neuropsychiatric Disorders
 - Princess Ballroom (Salon) A-E

Friday, May 30

REGISTRATON 7:30AM - 10AM

SPEAKER READY 7:30AM - 10AM

7:30AM - 9AM

Morning Break
Princess East Foyer

8:30AM - 10AM

Panel Sessions

- A BD2 Roadmap to Improve Heart and Diabetes Heath in Bipolar Disorder
 - Princess Ballroom (Salon) F
- New Clinical Trials for Autism: Endpoints, Study Design, Biomarkers and Results for a FAAH Inhibitor, GABA-B Agonist, Pregnenolone, and Vasopressin
 - Princess Ballroom (Salon) G
- New Targets, New Hope: Advances in Novel Treatment Discovery for Depression
 - Princess Ballroom (Salon) H
- Novel Treatments and Biomarkers for Cognitive Deficits in Mood Disorders
 - Princess Ballroom (Salon) I

ASCP | TUESDAY, MAY 27TH



9:00 a.m. - 10:30 a.m.

Panel Sessions

9:00 a.m. - 10:30 a.m.

*Using Group Medical Visits / Shared Medical Appointments to Improve Access to Care for Bipolar Disorder and Other Psychiatric Disorders: Evaluation of a Novel Service Delivery Model

Princess Ballroom (Salon) F

Chair: Sagar Parikh, University of Michigan, Ann Arbor

9:09 a.m. - 9:33 a.m.

Providing Specialized Care for Bipolar Disorders through Shared Medical Appointments Vijay Gorrepati, The University of Texas at Austin

9:33 a.m. - 9:57 a.m.

Group Medical Visits for Psychiatric Care: Pilots in Post-Crisis and Outpatient Care Kirsten Penner-Goeke, University of Manitoba

9:57 a.m. - 10:21 a.m.

Using Group Medical Visits / Shared Medical Appointments to Improve Resident Education and Enhance Access and Quality of Care for Bipolar Disorder

Sagar Parikh, University of Michigan, Ann Arbor

Discussant: Sagar Parikh, University of Michigan

9:00 a.m. - 10:30 a.m.

*^Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice

Princess Ballroom (Salon) G

Chair: Lydia Ann, University of California, Irvine

Co-Chair: Gemma Espejo, University of California, Irvine School of Medicine

9:09 a.m. - 9:27 a.m.

Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice

Hanadi Ajam Oughli, UCLA, Semel Institute

9:27 a.m. - 9:45 a.m.

Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice

Daniel Okobi, Advent Health

9:45 a.m. - 10:03 a.m.

Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice

Katy Lunny, University of California, Irvine

10:03 a.m. - 10:21 a.m.

Advancing Care in Geriatric Psychiatry: Updates in Diagnosis, Treatment, and Clinical Practice

Farah Khorassani, UCI

Discussant: Gemma Espejo, University of California, Irvine School of Medicine

9:00 a.m. - 10:30 a.m.

*^~Recent Advances in Ketamine and Esketamine: Research and Clinical Practice

Princess Ballroom (Salon) H

Chair: Joshua Rosenblat, University of Toronto

9:05 a.m. - 9:20 a.m.

Exploring Plasticity Mechanisms Across Psychological, Cognitive, and Neural Domains Following Ketamine Treatment for Depression

Rebecca Price, University of Pittsburgh

9:20 a.m. - 9:35 a.m.

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Data from the First 58 Months After Approval

Gerard Sanacora, Yale University

9:35 a.m. - 9:50 a.m.

Suicide-Related Biomarkers of Response to Ketamine

Elizabeth Ballard, National Institute of Mental Health

9:50 a.m. - 10:05 a.m.

Esketamine and Ketamine - Is There a Meaningful Difference?

Sara Di Luch, University Health Network

10:05 a.m. - 10:20 a.m.

Evaluating the Association Between Antidepressant Efficacy and Dissociation with Ketamine in Treatment-Resistant Bipolar Depression (TRBD)

Samuel Wilkinson, Yale School of Medicine

Discussant: Joshua Rosenblat, University of Toronto

9:00 a.m. - 10:30 a.m.

*Expanding the Reach of Clinical Trials: Including Patients with Suicidal Thoughts and Behavior

Princess Ballroom (Salon) I

Chair: Manish Jha, University of Texas Southwestern Medical Center

Co-Chair: Jill Harkavy-Friedman, American Foundation for Suicide Prevention

9:09 a.m. - 9:27 a.m.

Subtyping Suicidality: Breakthroughs and Challenges in Assessing the Neurobiology of Symptom Heterogeneity in Adults with Unipolar Depression

Katharine Dunlop, University of Toronto Faculty of Medicine

9:27 a.m. - 9:45 a.m.

Managing Suicidality in Clinical Trials for Prolonged Grief: An Example of Two Studies

Natalia Skritskaya, Columbia University

9:45 a.m. - 10:03 a.m

Regulatory Perspectives on Suicidal Ideations and Behaviors in Clinical Trials Zimri Yaseen, FDA/CDER/OND/ON/DP

10:03 a.m. - 10:21 a.m.

Including People with Suicidal Thoughts and Behaviors in Clinical Trials of Mood Disorders

Andrew Nierenberg, Massachusetts General Hospital

Discussant: Manish Jha, University of Texas Southwestern Medical Center

11:00 a.m. - 12:30 p.m. Panel Sessions

11:00 a.m. - 12:30 p.m.

*Reimagining Lithium – From Bedside to Bench

Princess Ballroom (Salon) F

Chair: Paul Keck, Lindner Center of HOPE/Univ of Cincinnati

11:09 a.m. - 11:33 a.m.

Reimagining Lithium - From Bedside to Bench

Paul Keck, Lindner Center of HOPE/Univ of Cincinnati

11:33 a.m. - 11:57 a.m.

Reimagining Lithium - From Bedside to Bench

Gary Sachs, Massachusetts General Hospital and Harvard Medical School

11:57 a.m. - 12:21 p.m.

Reimagining Lithium - From Bedside to Bench

Pablo Lapuerta, 4M Therapeutics

Discussant: Pablo Lapuerta, 4M Therapeutics

11:00 a.m. - 12:30 p.m.

*Alcohol and Cocaine Use Disorders: New Findings in Telehealth and Novel Treatment Approaches

Princess Ballroom (Salon) G

Chair: Lori Davis, Veterans Affairs Medical Center

11:09 a.m. - 11:33 a.m.

Interactions Between Ethanol and PT150, a Selective Glucocorticoid Receptor Antagonist, in Healthy Volunteers

Christopher Verrico, Baylor College of Medicine

11:33 a.m. - 11:57 a.m.

Psilocybin-Facilitated Treatment for Cocaine Use Disorder

Peter Hendricks, The University of Alabama at Birmingham

11:57 a.m. - 12:21 p.m.

Telehealth Services and Prescriptions for Medications in the Treatment of Alcohol Use Disorders are Associated with a Reduction in High Intensity Health Resource Utilization and Suicidality in Veterans

Lori Davis, Veterans Affairs Medical Center

Discussant: Ivan Montoya, DHHS/National Institute on Drug Abuse

11:00 a.m. - 12:30 p.m.

*Targeting Major Depressive Disorder Subtypes for Treatment Development. Selecting Optimal Assets from the Pipeline

Princess Ballroom (Salon) H

Chair: George Papakostas, Massachusetts General Hospital

Co-Chair: Manish Jha, University of Texas Southwestern Medical Center

11:09 a.m. - 11:27 a.m.

Pipeline for Major Depressive Disorder: Candidate Compounds for Drug Development in Depression with High Levels of Irritability

Manish Jha, University of Texas Southwestern Medical Center

11:27 a.m. - 11:45 a.m.

Novel Therapies for Pediatric Depression: Exploring the Pipeline for Best-Fitting Candidates.

Clotilde Guidetti, Massachusetts General Hospital, and Harvard Medical School

12:03 p.m. - 12:21 p.m.

Selecting Promising Treatment Leads for Insomnia in Major Depressive Disorder Venkat Bhat, University of Toronto

Discussant: Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

11:00 a.m. - 12:30 p.m.

*Optimizing and Developing Transcranial Magnetic Stimulation in the Veterans Affairs Healthcare System: Research Updates from the National TMS Program

Princess Ballroom (Salon) I

Chair: Alexandra Aaronson, Edward Hines VA Hospital

11:09 a.m. - 11:27 a.m.

Rethinking Suicidality in Veterans with Traumatic Brain Injury: Establishing a Treatment Target and Developing a Novel Frontal-Pole ITBS Protocol

Alexandra Aaronson, Edward Hines VA Hospital

11:27 a.m. - 11:45 a.m.

Sleep Dysfunction, Major Depression, and Transcranial Magnetic Stimulation: Results from the National VA TMS Clinical Pilot Program

Zachary Zuschlag, James A. Haley Veterans Hospital

11:45 a.m. - 12:03 p.m.

Modeling the TMS Antidepressant Response in Veterans

Yosef Berlow, Alpert Medical School, Brown University

12:03 p.m. - 12:21 p.m.

Impact of Medications on Clinical Outcome of Transcranial Magnetic Stimulation Treatment of Depression and PTSD in the VA Clinical TMS Program

F. Andrew Kozel, Florida State University

Discussant: F. Andrew Kozel, Florida State University

2:00 p.m. - 4:00 p.m.

Pharmaceutical Pipeline Session

Princess Ballroom (Salon) A - E

2:00 p.m. - 2:10 p.m.

Oral, Once-Daily LB-102 (N-methyl Amisulpride): Recent Positive Results from a Phase 2 Study in Patients with Acute Schizophrenia

John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

2:10 p.m. - 2:20 p.m.

TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust and Long-Lasting Activity in Phase 2

Jennifer Warner-Schmidt, Transcend Therapeutics

2:20 p.m. - 2:30 p.m.

Development of GATE-251, an Orally Bioavailable Positive Allosteric Modulator of the NMDA Receptor, to Treat Major Depressive Disorder in Subjects with Comorbid Insomnia and Anxiety

Anantha Shekhar, University of Pittsburgh

2:30 p.m. -2:40 p.m.

Robust Antidepressant Efficacy of the Novel 5-HT2A Receptor Agonist GM-2505 in a Double Blind, Randomized, Controlled Phase 2a Trial in Patients with MDD

Gerard Marek, Gilgamesh Pharmaceuticals, Inc.

2:40 p.m. - 2:50 p.m.

Once-Daily NBI-1117568, a Highly Selective Orthosteric M4 Muscarinic Receptor Agonist, Demonstrates Meaningful Improvements in Panss Total Score and is Well Tolerated in Adults with Schizophrenia: Phase 2 Study Results

Abigail Nash, Neurocrine Biosciences, Inc.

2:50 p.m. - 3:00 p.m.

Evaluating Augmentation of Anti-Suicidal Effects of Intravenous Ketamine by Low Oral Doses of Opioid Receptor Partial Agonism

Jason Tucciarone, Stanford University School of Medicine

2:50 p.m. - 3:00 p.m.

Targeting the KCNQ (a.k.a., Kv7) Potassium Channel as a Novel Treatment for Depression and Anhedonia: Initial Results from a Randomized, Controlled Trial of XEN1101 vs. Placebo in Adults with Major Depressive Disorder

James Murrough, Icahn School of Medicine at Mount Sinai

3:00 p.m. - 3:10 p.m.

The Entactogen, EMP-01, Represents a Novel Approach to the Treatment of Social Anxiety Disorder with its Pharmacological Selectivity and Distinct Subjective Effects Supportive of Safety and Therapeutic Utility

Sarah McEwen, atai Life Sciences

3:10 p.m. - 3:20 p.m.

Sustained Mood Improvement with Laughing Gas Exposure (SMILE): A Randomized, Placebo-Controlled Pilot Trial of Nitrous Oxide for Treatment-Resistant Depression Venkat Bhat, University of Toronto

3:20 p.m. - 3:30 p.m.

Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized, Controlled Trial

Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

4:15 p.m. – 6:15 p.m.

Workshops

4:15 p.m. - 6:15 p.m.

^Recent Results From NIMH-Funded Clinical Trials of Rapid Antidepressants to Reduce Suicide Risk

Princess Ballroom (Salon) F

Chair: Samuel Wilkinson, Yale School of Medicine

4:25 p.m. - 4:50 p.m.

Effectiveness and Implementation of a Brief, Rapid-Acting, Synergistic, Bio-Behavioral Treatment Among Hospitalized Inpatients Following a Suicide Attempt

Rebecca Price, University of Pittsburgh

4:50 p.m. - 5:15 p.m.

Ketamine Treatment in Youth for Fast Reduction of Suicidality and Engagement in Psychotherapy: An Ongoing Randomized Placebo Controlled Trial

Amit Anand, Harvard Medical School

5:15 p.m. - 5:40 p.m.

Cognitive Behavioral Therapy following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention (ENDURE-CBT)

Matthew Macaluso, The University of Alabama at Birmingham

5:40 p.m. - 6:05 p.m.

Making Progress in Clinical Trials for Suicide Prevention - Design and Conduct Considerations

Samuel Wilkinson, Yale School of Medicine

Discussant: Brandon Kitay, Emory University School of Medicine

4:15 p.m. - 6:15 p.m.

*#^+Navigating Research Career Trajectories: An Interactive Workshop and Toolkit for Building Teams, Nurturing Relationships, and Ethical and Inclusive Clinical Research Practice for the Long Haul

Princess Ballroom (Salon) G

Chair: Renee Martin-Willett, The University of Colorado Boulder **Co-Chair:** Rana Jawish, University of Utah School of Medicine

4:25 p.m. - 4:55 p.m.

Navigating Research Career Trajectories: An Interactive Workshop and Toolkit for Building Teams, Nurturing Relationships, and Ethical and Inclusive Clinical Research Practice for the Long Haul

Anita Clayton, University of Virginia

4:55 p.m. - 5:25 p.m.

Navigating Research Career Trajectories: An Interactive Workshop and Toolkit for Building Teams, Nurturing Relationships, and Ethical and Inclusive Clinical Research Practice for the Long Haul

Lealani Mae "Leah" Acosta, Vanderbilt University Medical Center

5:25 p.m. - 5:55 p.m.

Navigating Research Career Trajectories: An Interactive Workshop and Toolkit for Building Teams, Nurturing Relationships, and Ethical and Inclusive Clinical Research Practice for the Long Haul

Angela Bryan, The University of Colorado Boulder

4:15 p.m. - 6:15 p.m.

*Evolving Pharmacotherapy Targets in Mood Disorders: When the Old Meets the New, the Tried, and the True

Princess Ballroom (Salon) H

Chair: Carlos Zarate, National Institute of Mental Health

4:24 p.m. - 4:58 p.m.

When Retro is "In": The Place of Lithium, VPA, Tricyclics, and MAOIs in the 2025 Pharmacopoeia

Andrew Nierenberg, Massachusetts General Hospital

4:58 p.m. - 5:32 p.m.

Modulating the Glutamatergic, GABA-Ergic, and Opioid-Ergic Systems to Achieve Rapid Antidepressant Effects

Carlos Zarate, National Institute of Mental Health

5:32 p.m. - 6:06 p.m.

Selective Kappa Opioid Receptor Antagonists as Novel Therapeutic Targets for Major Depressive Disorder and Anhedonia

Sanjay J. Mathew, Baylor College of Medicine

Discussant: Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

4:15 p.m. - 6:15 p.m.

*Bipolar Disorder Versus Borderline Personality Disorder: A Clinical Conundrum Princess Ballroom (Salon) I

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai **Co-Chair:** Holly Swartz, University of Pittsburgh School of Medicine

4:20 p.m. - 4:45 p.m.

Screening for Bipolar Disorder and Finding Borderline Personality Disorder

Mark Zimmerman, Brown University

4:45 p.m. - 5:10 p.m.

The Researcher's Dilemma: Overlapping Phenomenology and Comorbidity

Holly Swartz, University of Pittsburgh School of Medicine

5:10 p.m. - 5:35 p.m.

Pharmacotherapies for Mood Instability: What Are We Treating?

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

5:35 p.m. - 6:00 p.m.

An Integrative Framework for Treatment Individuals with Comorbid Bipolar Disorder and Borderline Personality Disorder

Christina Temes, Harvard Medical School, Massachusetts General Hospital

Discussant: Stephen Strakowski, Indiana University School of Medicine

ASCP | WEDNESDAY, MAY 28TH



8:30 a.m. - 10:00 a.m.

Henry Nasrallah Awardee: Stephen Stahl

Princess Ballroom (Salon) A - E

8:30 a.m. - 10:00 a.m.

Teaching the Teachers of Psychopharmacology: Where Should the Focus be, on the Content, on the Presenter or on the Participant?

Chair: Henry Nasrallah, University of Cincinnati College of Medicine Co-Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

8:50 a.m. - 10:00 a.m.

Teaching the Teachers of Psychopharmacology: Where Should the Focus be, on the Content, on the Presenter or on the Participant?

Stephen Stahl, University of California San Diego

1:00 p.m. - 2:30 p.m.

Clinical Updates in Neurotherapeutics

Princess Ballroom (Salon) A - E

1:00 p.m. - 2:30 p.m.

Clinical Updates in Neurotherapeutics

Chair: Michael Henry, Massachusetts General Hospital **Co-Chair:** Alexandra Aaronson, Edward Hines VA Hospital

1:05 p.m. - 1:30 p.m.

The Sound of the Future? An Introduction to Low Intensity Focused Ultrasound

Noah Philip, Alpert Medical School of Brown University

1:30 p.m. - 1:55 p.m.

In the Age of Experimental Medicine and Precision Neuromodulation

Joan Camprodon, Massachusetts General Hospital, Harvard Medical School

1:55 p.m. - 2:20 p.m.

Vagus Nerve Stimulation for Treatment-Resistant Depression: The RECOVER Trial

Charles Conway, Washington University in St. Louis

1:55 p.m. - 2:20 p.m.

Vagus Nerve Stimulation for Treatment-Resistant Depression: Re-Evaluating Outcome Measures

Scott Aaronson, Sheppard Pratt

3:00 p.m. - 4:30 p.m.

Individual Research Reports (IRRs)

3:00 p.m. - 4:30 p.m.

~Individual Research Reports (IRRs): Innovations in Novel Therapeutics for Mood, Anxiety and Related Disorders

Princess Ballroom (Salon) H

Chair: Ritvji Satodiya, M.D.

3:00 p.m. - 3:20 p.m.

Rapid Noninvasive Modulation of Anterior Cingulate Cortex for Mood and Pain Disorders

Brian Mickey, University of Utah

3:20 p.m. - 3:40 p.m.

Assessing Cognitive Outcomes in Treatment-Resistant Depression following Psilocybin-Assisted Psychotherapy

Danica Johnson, University of Toronto

3:40 p.m. - 4:00 p.m.

Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Phase 3 PTSD Study

Spyros Papapetropoulos, Neuphoria Therapeutics Inc

4:00 p.m. - 4:20 p.m.

Phase 3 Trial Design and Methodology: Treatment With MM120 (Lysergide) for Generalized Anxiety Disorder and Major Depressive Disorder

Daniel Karlin, MD, MA, Mind Medicine Inc.

3:00 p.m. - 4:30 p.m.

Individual Research Reports (IRRs): Advances in Psychosis and Neurocognitive Disorders Research

Princess Ballroom (Salon) F

Chair: Snoben Kuruvila, PA-C

3:00 p.m. - 3:20 p.m.

Enhancing Drug Memory Forgetting in Drug addiction: The Neural Signature of Methylphenidate- And Reconsolidation-Enhanced Extinction in Cocaine Use Disorder

Ahmet Ceceli, Icahn School of Medicine at Mount Sinai

3:20 p.m. - 3:40 p.m.

Moderators of Antidepressant Treatment in Late-Life Treatment-Resistant Depression: an Analysis of the OPTIMUM Randomized Controlled Trial

Helena Kim, Centre for Addiction and Mental Health, University of Toronto

3:40 p.m. - 4:00 p.m.

Measurement of Schizophrenia Symptoms through Speech Phenotyping from Panss recordings: A Cross-Study Validation

Michelle Worthington, Brooklyn Health

4:00 p.m. - 4:20 p.m.

Could Right Medial Orbitofrontal Cortex Damage from Traumatic Brain Injury Play a Role in Suicidality? Pilot Neuroimaging Results Towards Development of a Novel Neurostimulation Treatment

Alexandra Aaronson, Edward Hines VA Hospital

3:00 p.m. - 4:30 p.m.

Individual Research Reports (IRRs): Update on Biomarkers Research

Princess Ballroom (Salon) G

Chair: Keren Bachi, Ph.D.

3:00 p.m. - 3:20 p.m.

Treating Acute Suicidality in a Medical Setting - Approach, Knowledge and Current Practices Around Ketamine Infusion

H. Nur Eken, University of Pittsburgh Medical Center

3:20 p.m. - 3:40 p.m.

Brain Age and Telomere Length in Participants with Major Depressive Disorder and Healthy Controls

Nefize Yalin, Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institute of Health

3:40 p.m. - 4:00 p.m.

Modeling Rapid Antidepressant Mechanisms in Treatment-Resistant Depression Using iPSC-Derived Neurons and CSF Proteomic Clinical Correlation

Gregory Jones, National Institute of Mental Health

4:00 p.m. - 4:20 p.m.

Cross-Frequency Dialogue During Sleep Is Disrupted in Depression

Samika Kumar, National Institute of Mental Health, NIH

3:00 p.m. - 4:30 p.m.

Individual Research Reports (IRRs): Bipolar Disorder

Princess Ballroom (Salon) I

Chair: Rana Jawish, M.D.

3:00 p.m. - 3:20 p.m.

Neurostructural Correlates of Polygenic Risk for Coronary Artery Disease in Relation to Youth Bipolar Disorder

Nidhi Kulkarni, Centre for Youth Bipolar Disorder, CAMH

3:20 p.m. - 3:40 p.m.

Cortisol Infusion Pumps and Their Impact on Psychiatric and Physiological Outcomes in Adrenal Insufficiency: A Translational Approach to Psychopharmacology

Ryan Berry, Authority Health, FQHC

3:40 p.m. - 4:00 p.m.

An Interim Blinding Integrity Analysis of a Randomized, Double-Blind, Midazolam-Controlled Phase II Clinical Trial Investigating Repeated Ketamine Infusions for Treatment Resistant Bipolar Depression

Diana Orsini, University of Toronto

4:00 p.m. - 4:20 p.m.

How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?

Mark Zimmerman, Brown University

7:00 p.m. - 8:30 p.m.

Satellite Symposium

Palomino 1 - 3

7:00 p.m. - 8:30 p.m.

Schizophrenia: What's New About Dopamine and How It is Regulated?

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

7:00 p.m. - 8:30 p.m. Schizophrenia: What's New About Dopamine and How It is Regulated?

Leslie Citrome, New York Medical College

ASCP | THURSDAY MAY 29TH



8:15 a.m. - 9:15 a.m.

Keynote Plenary: The New and the Old of is Newer Better

Princess Ballroom (Salon) A - E

8:15 a.m. - 9:15 a.m.

Keynote: The New and the Old of is Newer Better Chair: Carlos Blanco, National Institute on Drug Abuse

8:25 a.m. - 9:15 a.m.

The New and the Old of is Newer Better

Joshua Gordon, College of Physicians and Surgeons, Columbia University/New York State Psychiatry

9:30 a.m. - 11:30 a.m.

Update from Federal and Other Funding Agencies Plus

Princess Ballroom (Salon) A - E

9:30 a.m. - 11:30 a.m.

Update from Federal and Other Funding Agencies Plus

Princess Ballroom (Salon) A - E

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

Co-Chair: Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of Medicine at

Mount Sinai

9:35 a.m. - 9:58 a.m.

NIAAA Update: Focus on the Medications Development Program

Daniel Falk, NIAAA/NIH

9:58 a.m. - 10:21 a.m.

Patient-Centered Comparative Effectiveness Research

Yu-Ping Wang, Patient-Centered Outcomes Research Institute (PCORI)

10:21 a.m. - 10:44 a.m.

NIDA Update

Ivan Montoya, DHHS/National Institute on Drug Abuse

10:44 a.m. - 11:07 a.m.

Update from Defense Health Agency Psychological Health Research Portfolio

Fuad Issa, Defense Health Agency

11:07 a.m. - 11:30 a.m.

Update on VA Research Initiatives in Mental Health

Lori Davis, Veterans Affairs Medical Center

Discussant

Anita Clayton, University of Virginia SOM Dept of Psychiatry and Neurobehavioral Sciences

Discussant

Mark Rapaport, University of Utah Huntsman Mental Health Institute

1:15 p.m. - 2:45 p.m. Panel Sessions/Workshops

1:15 p.m. - 2:45 p.m.

*Can We Make Cognitive Enhancement a More Achievable Therapeutic Target in SMI Clinical Trials?

Princess Ballroom (Salon) F

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

1:24 p.m. - 1:48 p.m.

The Challenges of Treating the Cognitive Dysfunction of Dementia Praecox: A Major Unmet Need in Schizophrenia

Philip Harvey, University of Miami Miller School of Medicine

1:48 p.m. - 2:12 p.m.

Overcoming Methodological Obstacles to Improve Cognitive Dysfunction in Clinical Trials for Bipolar Disorder and Major Depression

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

2:12 p.m. - 2:36 p.m.

Novel Mechanisms Targeting Neurocognitive Dysfunction

Dan Iosifescu, New York University School of Medicine

Discussant: Nina Schooler, SUNY Downstate Health Sciences Center

1:15 p.m. - 2:45 p.m.

*~Novel Therapies for Individuals with Cocaine/Methamphetamine Use Disorder: Findings from Studies Within the NIDA Clinical Trials Network

Princess Ballroom (Salon) G

Chair: Manish Jha, University of Texas Southwestern Medical Center

1:24 p.m. - 1:42 p.m.

Drug Discovery for Stimulant Use Disorders Using Artificial Intelligence and Real-World Target Trial Emulation

Rong Xu, Case Western Reserve University

1:42 p.m. - 2:00 p.m.

Repetitive Transcranial Magnetic Stimulation for Stimulant Use Disorders (STIMULUS): Rationale and Preliminary Findings

Karen Hartwell, Medical University of South Carolina

2:00 p.m. - 2:18 p.m.

Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and its Association with Reduction in Methamphetamine Use in ADAPT-2 Trial

Abu Minhajuddin, The University of Texas Southwestern Medical Center

2:18 p.m. - 2:36 p.m.

Outcomes from the Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder

Mariah Kalmin, RAND Corporation

Discussant: Snoben Kuruvila, UTSW Medical Center Dallas

1:15 p.m. - 2:45 p.m.

^Re-Evaluating Methodologies in Psychiatric Clinical Trials: Lessons from Psychedelic Studies and Beyond

Princess Ballroom (Salon) H

Chair: Scott Aaronson, Sheppard Pratt

1:24 p.m. - 1:42 p.m.

Addressing the Issues of Functional Unblinding and Patient/Participant Expectations in the Current Landscape of Treatment Development

Gerard Sanacora, Yale University

1:42 p.m. - 2:00 p.m.

Are the Effects of Pharmacotherapy Ever Really Independent of Context? How Lessons from Psychedelic Clinical Trials May Help Us Better Understand Clinical Trial Results Across Psychiatry – and Design Better Trials in the Future

Rebecca Hendrickson, VA Puget Sound Health Care System

2:00 p.m. - 2:18 p.m.

Platform Trials for Pediatric Major Depressive Disorder and Other Indications

Manpreet Singh, University of California, Davis, School of Medicine

2:18 p.m. - 2:36 p.m.

Re-Thinking Depression Outcome Measures in Rapidly Acting and Slowly Acting Interventions

Scott Aaronson, Sheppard Pratt

1:15 p.m. - 2:45 p.m.

*^Practical Considerations for Deprescribing Psychiatric Medication

Princess Ballroom (Salon) I

Chair: Joshua Rosenblat, University of Toronto

1:23 p.m. - 1:41 p.m.

Psychological Factors Associated with Deprescribing Psychotropic Medications

Holly Swartz, University of Pittsburgh School of Medicine

1:41 p.m. - 1:59 p.m.

The Scourge of Anticholinergic Load

Leslie Citrome, New York Medical College

1:59 p.m. - 2:17 p.m.

The What, When, and How of Deprescribing Psychiatric Medications in Medically-Ill Older Adults

Rajnish Mago, Simple and Practical Medical Education, LLC

2:17 p.m. - 2:35 p.m.

Retrospective Tracking of the Value and Tolerability of Multiple Medications Prior to Deprescribing

Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC

Discussant: Mauricio Tohen, University of New Mexico

3:00 p.m. - 4:30 p.m.

Panel Sessions

3:00 p.m. - 4:30 p.m.

^Harnessing Educational Technology to Advance Education: The Next Generation ASCP Model Psychopharmacology Curriculum

Princess Ballroom (Salon) F

Chair: Matthew Macaluso, The University of Alabama at Birmingham

3:09 p.m. - 3:33 p.m.

Rebooting the ASCP Model Psychopharmacology Teaching Curriculum

Richard Shelton, University of Alabama at Birmingham

3:33 p.m. - 3:57 p.m.

Harnessing Educational Technology to Advance Education: The Next Generation ASCO Model Psychopharmacology Curriculum

Gemma Espejo, University of California, Irvine School of Medicine

3:57 p.m. - 4:21 p.m.

Rebooting the Next Generation Model Curriculum: What Residency Training Programs Need

Lillian Houston, Southern Illinois University

Discussant: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

3:00 p.m. - 4:30 p.m.

*A Healthy Mind in a Healthy Body: Findings from Translational Research Into Causes, Treatments, and Their Impacts

Princess Ballroom (Salon) G

Chair: Mahavir Agarwal, Centre for Addiction and Mental Health (CAMH)

3:09 p.m. - 3:33 p.m.

Interventions to Mitigate Psychotropic Associated Weight Gain Using an Algorithmic Measurement-Based Integrated Clinical Pathway: A Retrospective Chart Review Study Kateryna Maksyutynska, Centre for Addiction and Mental Health, University of Toronto

3:33 p.m. - 3:57 p.m.

Investigating the Effects of Antipsychotics on Brain Insulin Action: A Resting-State Functional Connectivity Study in Healthy Controls

Nicolette Stogios, Centre for Addiction and Mental Health, University of Toronto

3:57 p.m. - 4:21 p.m.

Assessing the Relationship Between PTSD and Type 2 Diabetes in a Large-Scale Analysis of Veteran Health Records

Katharine Liang, VA Puget Sound Health Care System

Discussant: Rebecca Hendrickson, VA Puget Sound Health Care System

3:00 p.m. - 4:30 p.m.

*Bipolar Action Network: A Prototype for a Learning Health Network

Princess Ballroom (Salon) H

Chair: Andrew Nierenberg, Massachusetts General Hospital

3:09 p.m. - 3:33 p.m.

Learning Health Systems: The Promise and the Challenge for Health Systems

Mark Rapaport, University of Utah Huntsman Mental Health Institute

3:33 p.m. - 3:57 p.m.

How Can a Learning Health Network Improve Care? The Use of Measurement and Practice Guidelines in Care for Mood Disorders

Erika Saunders, Penn State College of Medicine, Penn State Health

3:57 p.m. - 4:21 p.m.

Lessons from the Austin State Hospital Redesign: A Systems Approach

Stephen Strakowski, Indiana University School of Medicine

Discussant: A. Rush, Curbstone Consultant LLC

3:00 p.m. - 4:30 p.m.

^Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding

Princess Ballroom (Salon) I

Chair: Michael Henry, Massachusetts General Hospital

Co-Chair: Rebecca Hendrickson, VA Puget Sound Health Care System

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding

Scott Aaronson, Sheppard Pratt

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding

Rebecca Hendrickson, VA Puget Sound Health Care System

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding

M. Crismon, The University of Texas at Austin

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding: Finding Non-Federal Ways to Fund Your Academic Life

Michael Henry, Massachusetts General Hospital

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding: Are There Other Career Paths where You Can Do Research and Make a Difference?

Leslie Citrome, New York Medical College

3:10 p.m. - 4:20 p.m.

Charting a Course in Changing Times: Alternative Research Models Beyond Federal Funding

Manish Jha, University of Texas Southwestern Medical Center

4:30 p.m. - 6:30 p.m.

Plenary Panel

Princess Ballroom (Salon) A - E

4:30 p.m. - 6:30 p.m.

GLP-1 Agonists and Neuropsychiatric Disorders

Chair: Ivan Montoya, DHHS/National Institute on Drug Abuse

4:40 p.m. - 5:05 p.m.

GLP-1RAs in Severe Mental Illness - Opportunities and Challenges

Mahavir Agarwal, Centre for Addiction and Mental Health (CAMH), Canada

5:05 p.m. - 5:30 p.m.

GLP-1 and Neurodegenerative Diseases

Nigel Greig, National Institute on Aging, NIH

5:30 p.m. - 5:55 p.m.

Phase 2 Randomized Trials of GLP-1 Receptor Agonists for Substance Use Disorder Christian Hendershot, UNC at Chapel Hill

5:55 p.m. - 6:20 p.m.

The Neurobiology of GLP-1: from Physiology to Clinical Applications

Rodrigo Mansur, University of Toronto

ASCP | FRIDAY MAY 30TH



8:30 a.m. - 10:00 a.m.

Panel Sessions

8:30 a.m. - 10:00 a.m.

*A BD2 Roadmap to Improve Heart and Diabetes Heath in Bipolar Disorder

Princess Ballroom (Salon) F

Chair: Fernando Goes, Johns Hopkins University School of Medicine

8:39 a.m. - 9:03 a.m.

Clinical and Biological Determinants of Obesity and Inflammation in Bipolar-I Disorder: Insights from the BD2 Integrated Network Study

Balwinder Singh, Mayo Clinic

9:03 a.m. - 9:27 a.m.

Wellness Plans for Cardiovascular and Diabetes Health

Mark Frye, Mayo Clinic

9:27 a.m. - 9:51 a.m.

Concept of Change: Transforming Care Through Data-Driven Innovations for Treating Bipolar Disorder with Metabolic Comorbidities

Emily Baxi, Breakthrough Discoveries for Thriving with Bipolar Disorder

Discussant: Fernando Goes, Johns Hopkins University School of Medicine

8:30 a.m. - 10:00 a.m.

*#New Clinical Trials for Autism: Endpoints, Study Design, Biomarkers and Results for a FAAH Inhibitor, GABA-B Agonist, Pregnenolone, and Vasopressin

Princess Ballroom (Salon) G

Chair: Paul Wang, Clinical Research Associates, LLC

8:39 a.m. - 9:03 a.m.

Utility of Clinical Outcome Assessments and Biomarkers to Facilitate Drug Development Across Clinical Drug Development Phases - An Exemplar Proof-of-Concept Study

Gahan Pandina, Johnson and Johnson

9:03 a.m. - 9:27 a.m.

Canada and European Trials of Arbaclofen for Autistic Youth

Paul Wang, Clinical Research Associates, LLC

9:27 a.m. - 9:51 a.m.

Innovative Randomized Controlled Trials in Autism: From Neuropeptides to Neurosteroids

Antonio Hardan, Stanford University

Discussant: Evdokia Anagnostou, Holland Bloorview Kids Rehabilitation Hospital, University of Toronto

8:30 a.m. - 10:00 a.m.

*^New Targets, New Hope: Advances in Novel Treatment Discovery for Depression Princess Ballroom (Salon) H

Chair: James Murrough, Icahn School of Medicine at Mount Sinai

8:39 a.m. - 8:57 a.m.

KCNQ (Kv7) Potassium Channels as Novel Targets for Depression and Anhedonia James Murrough, Icahn School of Medicine at Mount Sinai

8:57 a.m. - 9:15 a.m.

Novel Immune Targets for Depression

Mina Rizk, Icahn School of Medicine at Mount Sinai

9:15 a.m. - 9:33 a.m.

The Lateral Habenula as a Novel Target for Antidepressant Development: Insights from Ketamine's Mechanistic Effects

Sara Costi, University of Oxford

9:33 a.m. - 9:51 a.m.

Hopelessness as a Treatment Target for Suicide Risk and Depression

Elizabeth Ballard, National Institute of Mental Health

Discussant: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

8:30 a.m. - 10:00 a.m.

*Novel Treatments and Biomarkers for Cognitive Deficits in Mood Disorders

Princess Ballroom (Salon) I

Chair: Adam Fijtman, NIH/NIMH

Co-Chair: Jessica Gilbert, National Institute of Mental Health

8:39 a.m. - 8:57 a.m.

Treatment-Resistant Depression Working Memory fMRI Brain Activity After IV Ketamine

Adam Fijtman, NIH/NIMH

8:57 a.m. - 9:15 a.m.

Ketamine Increases Reward Circuitry Connectivity in Depression: Evidence from Magnetoencephalography

Jessica Gilbert, National Institute of Mental Health

9:15 a.m. - 9:33 a.m.

Body Mass Index and Inflammation as Modifiable Targets for Addressing Obesity-Related Cognitive Impairment in Bipolar Disorder

Marzieh Majd, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School

9:33 a.m. - 9:51 a.m.

Novel Treatments to Improve Workplace and Psychosocial Function in Treatment-Resistant Depression: Exploratory Outcomes from an Open-Label Feasibility Trial of Psilocybin-Assisted Psychotherapy

Orly Lipsitz, University of Toronto

Discussant: Carlos Zarate, National Institute of Mental Health

ASCP | POSTERS



Wednesday, May 28, 2025

11:15 a.m. - 1:00 p.m.

Poster Session I with Lunch

Palomino Ballroom 4 - 10

W1. Translation and Validation Study of the Adult ADHD Investigator Symptom Rating Scale - Japanese (AISRS-Japanese)

Akira Iwanami, Dan Nakamura, Joan Busner*, Kensuke Ito, Nobutaka Sakayoshi, Dorothee Oberdhan, Sayaka Machizawa, Lenard A. Adler

Joan Busner, Signant Health and Virginia Commonwealth University School of Medicine

W2. Telehealth Psychotherapy and Healthcare Resource Utilization among Veterans with Alcohol Use Disorders: An Analysis of Nationwide Veterans Health Administration Data

Teresa Ann Granger, Joshua Richman, Regina Grebla, Lori Davis* Lori Davis, Veterans Affairs Medical Center

W3. Effects of Mazindol on Fentanyl Dependence: Preclinical Evidence from Study KO-943

Eric Konofal*, Jean-Charles Bizot, Maxime Robin, Anh-Tuan Lormier, Alexander Zwyer Eric Konofal, University of Paris, Robert-Debré Hospital, France

W4. Post-Launch Adverse Events Reported to FAERS for Long-Acting Injectable Buprenorphine

Brian Dawson, Michael P. Frost, Natalie R. Budilovsky-Kelley, Adam Friedman*, Joshua M. Cohen

Adam Friedman, Braeburn Inc, Plymouth Meeting, PA, USA

W5. Age of Onset of Social Anxiety Disorder (SAD) in Trials of Fasedienol (PH94B) Nasal Spray

Ester Salmán, Ross Baker, Stephen Coffey, Rita Hanover, Michael Liebowitz, Louis Monti, Ester Salman*

Ester Salman, Vistagen Therapeutics, Inc.

W6. Convergent Clinical and Preclinical Evidence Supports Sample Entropy as a Predictive Biomarker for Treatment Response to ALTO-300 in Major Depressive Disorder

Michael Avissar*, Guhan Sundar, Yueqi Guo, Li Shen, Joshua Jordan, Akshay Ravidran, Michael Larson, Scott Steffenson, Priyanka Takle, Stacey Eckert, Nicholas Cooper, Chao Wang, Maimon Rose, Faizan Badami, Jessica Powell, Amit Etkin, Patricio O'Donnell, Adam Savitz

Michael Avissar, Alto Neuroscience

ASCP | POSTERS



W7. Nonlinear Modeling of Depression and Anxiety Outcomes with Bilateral TMS Protocols

Yosef Berlow*, Amourie Prentice, Farrokh Mansouri, Victoria Middleton, Jennifer Bowman, Joseph Kriske, Nancy Donachie, Noah Philip, Jonathan Downar Yosef Berlow, Alpert Medical School, Brown University

W8. The Complex Diagnostic Profile of Psychiatric Outpatients Presenting for the Treatment of Bipolar Depression: Implications for the Generalizability of Placebo-Controlled Studies of Bipolar Depression

Mark Zimmerman*, Barbara Lu

Mark Zimmerman, Brown University

W9. The Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: Protocol and Interim Analysis of an Emotional-Processing fMRI Pilot Study

Erica Kaczmarek*, Ishrat Husain, Colin Hawco, Danica Johnson, Noah Chisamore, Zoe Doyle, Joshua Rosenblat

Erica Kaczmarek, University of Toronto

W10. Efficacy of Aripiprazole Once-Monthly and Aripiprazole 2-Month Ready-To-Use on Sleep Disruption in People with Bipolar I Disorder: Post Hoc Analyses of Data from Two Randomized Controlled Trials

Karimah S. Bell Lynum*, Anne Walker, Norman Atkins, Zhen Zhang, Craig Chepke, Joseph F. Goldberg

Karimah S. Bell Lynum, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

W11. Protocol for a Randomized, Double-Blind, Midazolam-Controlled Phase II Clinical Trial Investigating Repeated Ketamine Infusions for Treatment Resistant Bipolar Disorder (NCT05004896)

Diana Orsini*, Sara Di Luch, Tayyeba Shaikh, Roger McIntyre, Rodrigo Mansur, Joshua Rosenblat

Diana Orsini, University of Toronto

W12. Protocol for an Open-Label Extension Trial Investigating Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression (NCT05339074)

Sara Di Luch*, Diana Orsini, Tayyeba Shaikh, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat

Sara Di Luch, University Health Network

W13. Ketamine Versus Electroconvulsive Therapy for Non-Psychotic Treatment-Resistant Depression: A Cost-Effectiveness Analysis

Michael Lebenbaum, Benoit Mulsant, Sagar Parikh, Jason Fletcher, Jeffrey Hoch, Paul Kurdyak, Daniel Blumberger, Manish Jha, Venkat Bhat* Venkat Bhat, University of Toronto



*W14. Sustained Mood Improvement with Laughing Gas Exposure (SMILE): A Randomized, Placebo-Controlled Pilot Trial of Nitrous Oxide for Treatment-Resistant Depression

Karim Ladha, Jiwon Lee, Gabriella Mattina, Janneth Pazmino-Canizares, Duminda Wijeysundera, Fatemeh Nezhad, Vanessa Tassone, Fathima Adamsahib, Wendy Lou, Sidney Kennedy, Venkat Bhat*

Venkat Bhat, University of Toronto

W15. Alzheimer's Disease Specific Differences in Engagement by Gender for Online Clinical Trial Recruitment

Ralph Lee*, Yu-Jay Huoh, Colin Sholes, Craig Lewin Ralph Lee, Irvine Clinical Research

W16. Assessing the Relationship Between Dissociation and Esketamine Efficacy in Adults with Major Depression Disorder and Acute Suicidal Ideation or Behavior

Dionne Williams*, Dong Jing Fu, Carla Canuso

Dionne Williams, Janssen Pharmaceuticals and Drexel University

W17. Are Your SF Ratios Increasing? The Serial Screener, a Variant of the Professional Subject

Thomas Shiovitz*, Chelsea Steinmetz, Brittany Steinmiller, Brett Burbidge Thomas Shiovitz, CenExel CNR | CTSdatabase

W18. Practical Considerations for the Evaluation of Physical Dependence and Drug Withdrawal for Novel CNS-Active Drugs in Clinical Trials

Beatrice Setnik*, Jadwiga Martynowicz, Anthony Coulson, Sanjay Dube, Samiran Ghosh, Denise Milovan, Collin Price, Joyce Tsai, Berra Yazar-Klosinski, Gary Zammit Beatrice Setnik, Altasciences

W19. Can Improvements in Metabolic Health Impact Cognitive Outcomes in Individuals with Mood Disorders? Real-World Data from a Mental Health and Metabolism Clinic

Kateryna Maksyutynska*, Nicolette Stogios, Riddhita De, Femin Prasad, Akash PrasannaKumar, Tariq Ahmed, Vittal Korran, Marcos Sanches, Daphne Korczak, Ariel Graff-Guerrero, Gary Remington, Margaret Hahn, Sri Mahavir Agarwal

Kateryna Maksyutynska, Centre for Addiction and Mental Health, University of Toronto

W20. New Meta-Analytic Results Informing a Prospective Trial of Psilocybin for Cancer-Related Existential Distress

Samantha Lim*, Maria Lapid

Samantha Lim, Our Lady of Fatima University, Manila, Philippines

W21. Comparison of Mortality and Morbidity Risk with Monoclonal Antibodies: Data from Medical and Statistical Reports from US FDA for Seven Approved Medications Consisting of a Total Database of 19,721 Subjects

Aishwarya Prasad*, Anshu Arora, Arun Arora, Arifulla Khan Aishwarya Prasad, Northwest Clinical Research Center



W22. The National Pregnancy Registry for Psychiatric Medications: Risk of Major Malformations Following Fetal Exposure to Second Generation Antipsychotics

Lee Cohen*, Marlene Freeman, Parker Killenberg, Ellen Sojka, Caroline Frisch, Audrey Reuman, Maya Verghese, Hannah Yoon, Emma Grassi, Bridget Murphy, Peri Barest, David Chitayat, Sonia Hernandez-Diaz, Adele Viguera

Lee Cohen, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, MA

*****W23. Evaluating Augmentation of Anti-Suicidal Effects of Intravenous Ketamine by Low Oral Doses of Opioid Receptor Partial Agonism

Jason Tucciarone*, Igor D. Bandeira, Ian H. Kratter, Jarrod Ehrie, Christine Blasey, Boris D. Heifets, Alan F. Schatzberg

Jason Tucciarone, Stanford University School of Medicine, Department of Psychiatry

W24. Effects of COMP360 on Anhedonia-Related Items of the Montgomery-Asperg Depression Rating Scale (MADRS) and Positive and Negative Affect Scales (PANAS)

Matt Young*, Joyce Tsai, Claudia Sisa, Lindsay Marwood, Jamie Chai-Reese, Sunil Mistry, Guy Goodwin

Matt Young, Compass Pathways, PLC

W25. Initiating Dextromethorphan 45 Mg-Bupropion 105 Mg (Auvelity®) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations

Anita Clayton*, Gus Alva, Philip Bowman, Erin Crown, Bibi Das, Paul Doghramji, Brooke Kempf, John Miller, Andrew Muzyk, Jeremy Schreiber

Anita Clayton, University of Virginia SOM Dept of Psychiatry and Neurobehavioral Sciences

W26. Efficacy and Safety of a Single Administration of the N-Methyl-D-Aspartate Subunit 2B-Selective Negative Allosteric Modulator, BI 1569912, in People Living with Major Depressive Disorder: A Phase IB Randomized Controlled Trial

Roger S. McIntyre, Gerard Sanacora*, David P. Walling, Elan A. Cohen, Shishuka Malhotra, Holger Rosenbrock, Manuela Schmitz, Andreas Scholz, Sigurd D. Suessmuth, Franco De Crescenzo

Gerard Sanacora, Yale University, New Haven, CT, USA

W27. Fetal Brain Changes from in Utero Exposure to SSRIs

Emily Leiderman*, Madison Johnson, Mujeeb Shad

Emily Leiderman, Touro University Nevada

W28. Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin for Depression: Preliminary Results

David Liebers*, Umit Tural, Dan Iosifescu

David Liebers, New York University School of Medicine



W29. Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results from a Six-Month Open-Label Extension Study

Willie R. Earley, Suresh Durgam, Susan Kozauer*, Changzheng Chen, Tobie Escher, Andrew J. Cutler

Susan Kozauer, Intra-Cellular Therapies, Inc.

W30. The Effects of Adjunctive Cariprazine in Patients with Major Depressive Disorder with and Without Comorbid Anxiety Symptoms: A Post Hoc Analysis

Maurizio Fava, Jun Yu, Elizabeth Pappadopulos, Simranpreet Waraich* Simranpreet Waraich, AbbVie, North Chicago, IL, USA

W31. Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Phase 3 Trial

Suresh Durgam, Willie R Earley, Susan G Kozauer, Changzheng Chen, Hassan Lakkis, Margaret Martin*, Roger S. McIntyre, Stephen Stahl Margaret Martin, Intra-Cellular Therapies, Inc.

W32. Real-World Practice Patterns and Outcomes in Patients with Major Depressive Disorder Treated with Antidepressants

Maurice Ohayon, Maggie McCue, Michael Martin*, Patricia Driscoll-Shempp, Michelle Kirby, Andrew D. Krystal, Stephanie Duhoux, Marie-Lise Cote Michael Martin, Takeda Pharmaceuticals North America, Inc.

W33. The Association Between Amygdalar Subfiled Volume Changes and Depressive Symptom Improvements After Repeated Ketamine Infusion in Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Trial

Kengo Yonezawa*, Shinichiro Nakajima, Nobuaki Hondo, Yohei Ohtani, Kie Nomoto-Takahashi, Taisuke Yatomi, Sota Tomiyama, Nobuhiro Nagai, Keisuke Kusudo, Koki Takahashi, Shiori Honda, Sotaro Moriyama, Shinsuke Koike, Hiroyuki Uchida, Hideaki Tani

Kengo Yonezawa, Department of Neuropsychiatry, Keio University School of Medicine

W34. Secondary Analysis of the Effect of Patient Treatment Preference on the Clinical Outcomes in Subjects with Treatment Resistant Depression Enrolled in Ascertain-TRD Study

Stefania Chaikali*, Clotilde Guidetti, Madhukar Trivedi, Richard Shelton, Dan V. Iosifescu, Michael E. Thase, Manish Jha, Sanjay J. Mathew, Charles DeBattista, Mehmet Dokucu, Olga Brawman-Mintzer, William V. McCall, Matthew Macaluso, Maurizio Fava, George Papakostas

Stefania Chaikali, Harvard Medical School/Massachusetts General Hospital

W35. Supervised Machine-Learning Classification of Treatment-Resistant Depression in U.S. Claims Data

Vicki Wing*, Jason Lerner, Patrick Clarke, Shane O'Connor, Sydney Tran, Jonathan Darer, Jaspreet Gill, Lucinda Orsini

Vicki Wing, Compass Pathways



W36. Aripiprazole or Bupropion Augmentation vs Switching to Bupropion in Treatment Resistant Depression: A Benefit-Risk Analysis

William Meyerson*, Jordan Smoller

William Meyerson, Massachusetts General Hospital

W37. RE104: A Novel Serotonergic Psychedelic 4-OH-DiPT Prodrug

Mark Pollack*, Jasna Hocevar-Trnka, Beatrix Taylor, Robert Alexander, Nathan Bryson Mark Pollack, Reunion Neuroscience

W38. Enhancement of Cognition in Preclinical Models by Novel Investigational M1/M4 Agonist, ML-007

Susmita Chatterjee, Abraham Vazquez, Revathi Kaduru, Hannah K Kim, Maritza Soria, Natalie Navarro, Kimberly R Thompson*, James Lillie, Anatol C Kreitzer, Michael W Wood Kimberly R Thompson, MapLight Therapeutics

W39. Lysergide May Enhance Neuroplasticity by Post-Dose Upregulation of TrkB Compared to Other Compounds

Julie Tripp, MS RVT DABT*, Deborah Rudin, PhD, Oliver V. Stöckmann, MSc, Matthias E. Liechti, MD, Gennady N. SmaginPhD

Julie Tripp, MS RVT DABT, Mind Medicine Inc.

W40. Developing a New Neuroplastogen, ITI-1549, a Serotonin 5-HT2a Agonist for the Treatment of Neuropsychiatric Disorders

Emma Lehmann*, Sophie Dutheil, Lei Zhang, Neelu John, Nora Awadallah, Wei Yao, Peng Li, Gretchen Snyder, Robert Davis

Emma Lehmann, Intra-Cellular Therapies, Inc.

W41. The SIRT6 Activator, Forvisirvat (SP0624), Shows Pro-Cognitive and Antidepressant Effects on qEEG Brain Analytics: A Phase 1 Study

Walter Duffy, Joel Raskin, Gil Issachar, Offir Laufer, Chuck Moser, Kelly Abernathy, Greg Rigdon*

Greg Rigdon, Arrivo Bioventures

W42. Real-World Sleep Medication Treatment Patterns for Patients with Bipolar I Disorder, Schizophrenia, or Major Depressive Disorder Before and After Cariprazine Initiation

Roger S. McIntyre, Lauren Aronin*, Huy-Binh Nguyen Lauren Aronin, AbbVie, North Chicago, IL, USA

W43. Mood Trial Results: Multicenter Randomized Controlled Trial of a Home-Use External Combined Occipital and Trigeminal Afferent Stimulation Therapy for Major Depression

Jeffrey Rado*, Andrew Leuchter, Mark George, Linda Carpenter

Jeffrey Rado, Northwestern University Dept of Psychiatry and Behavioral Sciences



W44. A Pilot Study of Sequenced TMS and aTBS Dosing in Adolescents with Major Depressive Disorder

Cicek Bakir*, Paul A. Nakonezny, Dicle Buyuktaskin, Lucero Sangster-Carrasco, Irem Azamet, Jennifer Vande Voort, Paul E. Croarkin

Cicek Bakir, Mayo Clinic, Dept. Psychiatry and Psychology

W45. Predicting Depression Treatment Outcomes Using Mobile Health (mHealth) Technology

Jayesh Kamath*, Soumyashree Sahoo, Dongjiin Song, Alexander Russel, Bing Wang Jayesh Kamath, University of Connecticut Health Center

W46. Memantine and Memantine-Acetylcysteine Combination for Treatment-Resistant Obsessive-Compulsive Disorder

Christy Alhannat*, Kristine Hawkins, Maju Koola Christy Alhannat, Cooper Medical School

W47. Compliance with 2017 FDA Guidance for Evaluating Drug Impaired Driving: Application of Guidance to Approved Drugs Through 2024

Gary Kay*, Thomas Hochadel, Brandy Isaacks Gary Kay, Cognitive Research Corporation

W48. A Model Psychopharmacology Curriculum for Teachers of Psychiatric Residents and for Medical Students

Ira Glick*

Ira Glick, Stanford University School of Medicine

W49. Psychotherapy Experience Affects Antidepressant Response Rate Modeled Using the Participant and Clinician Reported (PCR) Circumplex Model of Depression

Hadley Nolan*, Zach Cole, Miriam Evans

Hadley Nolan, Adams Clinical

W50. Leveraging Genetic Approaches to Advance the Understanding of Genetic and Environmental Effects on Severe Mental Illness: The Moderating Role of Physical Activity

Olaoluwa Okusaga*, Roseann E. Peterson, Tim Bigdeli, Rachel L. Kember Olaoluwa Okusaga, Michael E DeBakey VA Medical Center/Baylor College of Medicine

W51. Duration of Illness and Response to Pimavanserin in Parkinson's Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data

Khashayar Dashtipour, Alberto Espay, Michele Tagliati, Gregory Brunson, Xiaoshu Feng, Nazia Rashid, Lambros Chrones*

Lambros Chrones, ACADIA Pharmaceuticals Inc



W52. Feasibility of Accelerated Course of Repetitive Transcranial Magnetic Stimulation in Methamphetamine Use Disorder

Amrita Ghose*, Taylor Helmbrecht, Virgilio Garza, Snoben Kuruvila, Sidarth Wakhlu, Madhukar Trivedi, Manish Jha

Amrita Ghose, The University of Texas Southwestern Medical Center, Department of Psychiatry

W53. Lurasidone and Pregnancy: An Update from the MGH National Pregnancy Registry for Psychiatric Medications

Marlene Freeman*, Adele Viguera, Maya Verghese, Hannah Yoon, Caroline Frisch, Audrey Reuman, Peri Barest, Emma Grassi, Bridget Murphy, David Chitayat, Sonia Hernandez-Diaz, Lee Cohen

Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, MA

W54. Treatment of Aripiprazole Associated Agalactorrhea with Risperdal: Case Series

Parmis Fatih*, Genevieve Kurapaty, Senada Bajmakovic-Kacila, Mervat Sha'ini Parmis Fatih, Rush Medical College of Rush University

W55. Clozapine Availability at United States Mental Healthcare Facilities

Samuel Bunting, Aparna Das*, Luca Lacobelli, Beth Broussard, Emily Griner, Robert Cotes Aparna Das, Emory University School of Medicine Department of Psychiatry

W56. Fetal Brain Changes from In-Utero Exposure to Antipsychotics

Golden Reeves*, Plaiphon Vaidyanuvatti, Mujeeb Shad Golden Reeves, Touro University Nevada

W57. Broad Efficacy of Xanomeline and Trospium Chloride Across Demographic Subgroups in the Long-Term EMERGENT-4 and EMERGENT-5 Trials of People with Schizophrenia

Amy Claxton*, Inder Kaul, Tejendra R Patel, Soumya A Charturvedi, Wei-Chih Lin Amy Claxton, Bristol-Myers Squibb

W58. Long-Term Safety and Tolerability of Xanomeline/Trospium in Schizophrenia: Incidence, Onset, and Duration of Treatment-Related Adverse Events in the 52-Week, Open-Label Extension EMERGENT-4 Trial

Amy Claxton*, Soumya A Charturvedi, Tejendra R Patel, Nichole Neugebauer, Pierre Nicolas, Inder Kaul

Amy Claxton, Bristol-Myers Squibb

W59. Efficacy and Safety of Strategies for Switching to Xanomeline and Trospium Chloride from Standard of Care Atypical Antipsychotics: Design of a Planned Open-Label Trial in People with Schizophrenia

David Walling*, Pierre Nicolas, Naomi Marbot, Lauren White, Eliesha Daniels David Walling, CenExel - CNS



W60. Trauma, Mental Disorders, and Suicide: A Retrospective Chart Review in an Urban Emergency Center

Ynhi Thomas*, Nidal Moukaddam, Syed Murtaza, Kelly Keene, Christopher Verrico, Nicholas Murphy, Sanjay Mathew, Thomas Kosten, Alan Swann

Ynhi Thomas, Henry J.N. Taub Department of Emergency Medicine; Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center

W61. Developing a Neuroeconomically Informed and Biologically Constrained Regret Inventory

Romain Durand de Cuttoli, Alexandra Fink, Austin Baggetta, Giorgio Coricelli, Helen Mayberg, A. David Redish, James Murrough, Xiaosi Gu, Ignacio Saez, Laurel Morris, Jonathan DePierro, Brian Sweis*

Brian Sweis, Icahn School of Medicine at Mount Sinai

W62. Single-Dose COMP360 Psilocybin for Post-Traumatic Stress Disorder

Niall McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Hollie Simmons, Agata Tofil-Kaluza, Shriya Das, Guy Goodwin*

Guy Goodwin, Compass Pathfinder Ltd. (a subsidiary of Compass Pathways plc), London, UK

*W63. Robust Antidepressant Efficacy of the Novel 5-HT2A Receptor Agonist GM-2505 in a Double Blind, Randomized, Controlled Phase 2a Trial in Patients with MDD

Gerard Marek*, Daniel Umbricht, Edward Christian, Jason Winters, Shane Raines, William Leong, Laszlo Kiss, Zoe Hughes, Robert Berman, Jorge Quiroz, Andrew Kruegel, Jonathan Sporn

Gerard Marek, Gilgamesh Pharmaceuticals, Inc.

★W64. Once-Daily NBI-1117568, a Highly Selective Orthosteric M4 Muscarinic Receptor Agonist, Demonstrates Meaningful Improvements in PANSS Total Score and is Well Tolerated in Adults with Schizophrenia: Phase 2 Study Results

Abigail Nash*, Elia E. Acevedo-Diaz, Kurt Olson, Satjit Brar, Ashley Whitcomb, Eiry Roberts, Samir Siddhanti, Jaskaran Singh

Abigail Nash, Neurocrine Biosciences, Inc.

*W65. Oral, Once-Daily LB-102 (N-methyl Amisulpride): Recent Positive Results from a Phase 2 Study in Patients with Acute Schizophrenia

Anna Eramo, Leslie Callahan, Niccolo Bassani, Baker P. Lee, Zachary Prensky, Andrew R Vaino, John Kane*

John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

W66. A Novel Combination Pharmacotherapeutic Platform for Substance Use Disorder Treatment

Tong Lee*

Tong Lee, Generys Biopharmaceuticals Corp.



W67. Evaluating the Correlation Between the Efficacy of MM120 (Lysergide) in Generalized Anxiety Disorder and Self-Reported Mystical Experience

Todd Solomon, PhD*, Sarah M. Karas, PsyD, Alexander Deschamps, MSW, Miguel A. Pinheiro, PhD, Daniel R. Karlin, MD, MA

Todd Solomon, PhD, Mind Medicine Inc.

W68. Initial Findings from the ASCP Task Force Delphi Panel on the Deprescribing of Psychiatric Medications

Joseph Goldberg*, Roger McIntyre, Rajnish Mago, Holly Swartz, Joshua Rosenblat, Michael Ostacher, Marlene Freeman, Mauricio Tohen, Michael E. Thase, Leslie Citrome, Swapnil Gupta

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

W69. Azetukalner, a Novel, Potent KV7 Potassium Channel Opener in Development for Major Depressive Disorder and Bipolar Depression: Updates from the Ongoing Clinical Programs

Noam Butterfield, Celene Grayson, Danny Lee, Erin MacKenzie, Joe McIntosh, Rostam Namdari, Anna Osmukhina, Jenny Qian, Christopher Kenney, Aleksandar Skuban* Aleksandar Skuban, Xenon Pharmaceuticals Inc.

W70. Pre-Treatment Body Mass Index as a Marker of Antidepressant Response to Ketamine: Preliminary Findings of a Large-Scale Meta-Analysis

Gustavo Medeiros*, Ian Qian, Darcy Curtis, Balwinder Singh, Brittany O'Brien, Sagar Parikh, Mark Kvarta, Lace Riggs, Annabelle Belcher, Eric Goldwaser, Mikael Tiger, Johan Lundberg, Bo Hu, Amit Anand, Gustavo Vazquez, Rebecca Price, Sanjay Mathew, Todd Gould, Carlos Zarate Jr, Fernando Goes

Gustavo Medeiros, University of Maryland School of Medicine

W71. COMP005 and COMP006: Example Approaches to Challenges in Randomized-Controlled Clinical Trials with Psychedelics

Matt Young, Caroline Hostetler*, Claudia Sisa, Guy Goodwin Caroline Hostetler, Compass Pathfinder Ltd.

W72. Seltorexant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder in the One Year Open Label Extension

Gahan Pandina*, Michael E. Thase, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Carla M. Canuso, Thomas Laughren, Wayne C. Drevets Gahan Pandina, Johnson and Johnson, Titusville, NJ

W73. Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adults with Treatment-Resistant Depression Based on Oral Antidepressant Status at Study Entry: A Post Hoc Analysis

Andrew J. Cutler, Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera*, Oliver Lopena, Lisa Lim, Muhammad Ahmed, Dillon McGovern

Patricia Cabrera, Johnson and Johnson, Titusville, NJ



W74. TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder

Amanda Jones*, Jennifer Warner-Schmidt, Martin Stogniew, Blake Mandell, Hannah Kwak, Terence Ching, Benjamin Kelmendi

Amanda Jones, Transcend Therapeutics

W75. Results from a Phase 2 Randomized Controlled Trial of Luvadaxistat in Cognitive Impairment Associated with Schizophrenia: The Erudite Study

Ni Khin*, Reuben H. Fan, Tingting Ge, Hans S. Klein, Jacob Ballon, Satjit Brar, Philip D. Harvey, Joshua Kantrowitz, Richard S.E. Keefe, Eiry Roberts, Jaskaran B. Singh Ni Khin, Neurocrine Biosciences, Inc.

W76. Switching from Antipsychotic Agents to Ulotaront in Participants with Schizophrenia: A Phase 3 Open-Label Study

David Crandall, Nicholas DeMartinis, Brian Rothman*, Heather Dworak, Michael Tocco, Courtney Zeni

Brian Rothman, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

W77. A Phase 4, Open-Label, Multicenter, Two-Cohort, Two-Period, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Participants with Schizophrenia

Jenna Hoogerheyde*, Rachel Dyme, Daniel Tatosian, Andrew Miller, David Walling, Elan Cohen, Kimball Johnson, Katrin Kupas, Ranjan Tiwari, Ken Kramer Jenna Hoogerheyde, Bristol-Myers Squibb

W78. Brilaroxazine's Effects on Efficacy, Safety, Adherence, and Biomarkers in the Phase 3 Recover 12-Month Open-Label Trial Extension in Patients with Stable Schizophrenia

Laxminarayan Bhat*, Seema R Bhat, Arulprakash Ramakrishnan, Wasim Khan, Simeen Khan

Laxminarayan Bhat, Reviva Pharmaceuticals, Inc.

W79. Valbenazine Improves the Impacts and Symptoms of Tardive Dyskinesia: Topline Results from the Phase 4 KINECT-PRO Study

Eduardo Dunayevich, M. Mercedes Perez-Rodriguez, Joseph McEvoy, Ashok Parameswaran*, Morgan Bron, Ericha Franey, Donna Sparta, Cathy Zeng, Susan D. Mathias, Christoph U. Correll

Ashok Parameswaran, Neurocrine Biosciences, Inc.



W80. A Phase Ib Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of the Novel Neuroplastogen DLX-001 in Participants with Major Depressive Disorder: Interim Findings

Aaron Koenig*, Renger Tiessen, Nicholas Pelletier, Daniel Gillie, Sydney DeCaro, Joi Dunbar, Kurt Rasmussen, David Olson, Eliseo Salinas

Aaron Koenig, Delix Therapeutics

W81. Advancing Tardive Dyskinesia Management through Targeted Education: A Six-Month Real-World Evaluation

Soumya Staton*, Margaret Harris, Jovana Lubarda, Jordan Schwartz, Katie Lucero, Denise Vanacore Chase, Leslie Citrome, Christoph Correll

Soumya Staton, Medscape Education

W82. IV Ketamine vs. Esketamine for Depression: A Systematic Review and Meta-Analysis

Ahmed Elmosalamy*, Idil Tarikogullari, Liliana Patarroyo Rodriguez, Gwen Wilson, Balwinder Singh

Ahmed Elmosalamy, Mayo Clinic, Dept. Psychiatry and Psychology

W83. Management of First Episode Psychosis: Psychopharmacology and Therapeutic Interventions

Saba Saleem, Sukhpreet Badesha*, Darakhshan Adam, Faisal Suba, Mujeeb Shad Sukhpreet Badesha, Idaho College of Osteopathic Medicine

W84. Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study

Jacob S. Ballon, Christina Arevalo*, Martin Dunbar, Alexandra Lovett, Christoph U. Correll Christina Arevalo, Alkermes, Inc., Waltham, MA

W85. Non-Clinical Efficacy and Safety of SUVN-L3307032, a Muscarinic M4 Positive Allosteric Modulator (M4 PAM), for the Treatment of Neuropsychiatric Symptoms Associated with Schizophrenia and Alzheimer's Disease

Ramakrishna Nirogi, VIjay Benade, Renny Abraham, Venkatesh Goura, Rajesh Kallepalli, Rajesh Babu Medapati, Onamala Varalakshmi, Kumar Bojja, Aamer Shaikh, Rajesh kumar Badange, Sravanthi Manchineella, Tirumala Narasimhula, Ankit Das, Naga Sai Soma Chandra Sekhar Guduru, Keerthi Sai Bitra, Anil Shinde*

Anil Shinde, Suven Life Sciences Limited

W86. Precision in Psychiatry Trials: A Novel Mathematically Augmented Machine Learning Approach for Identifying Patient Personas for Tailored Antipsychotic Therapy the Catie Schizophrenia Trial

Joseph Geraci, Bessi Qorri, Paul Leonchyk, Adam Gogacz, Larry Alphs, Luca Pani, Larry Alphs*

Larry Alphs, Denovo Biopharma LLC



W87. Clozapine Augmentation With Antipsychotics Among Patients in the Forensic Psychiatry System in Ontario

Mark Kaggwa, Joan Abaatyo, John Bradford, Gary Chaimowitz, Andrew Olagunju* Andrew Olagunju, McMaster University

W88. Physical Activity and Mental Health Among Individuals in Incarceration: A Systematic Review

Paige Harris, Sarah Lalji-Mawji, Kairavi Parikh, Britta Ostermeyer, Andrew Olagunju* Andrew Olagunju, McMaster University

Thursday, May 29, 2025

11:30 a.m. - 1:15 p.m.

Poster Session II with Lunch

Palomino Ballroom 4 - 10

T1. The Brain Connectome During Rest Shows Interaction Between Cocaine Use Disorder and Childhood Maltreatment

Keren Bachi*, Tien T. Tong, Yasmin L. Hurd, Keren Bachi

Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of Medicine at Mount Sinai

T2. Impact of Individual Baseline Factors on Opioid-Negative Urine Samples: Comparing Treatment with Weekly/Monthly Injectable Buprenorphine vs Daily Sublingual Buprenorphine/Naloxone in Patients with Opioid Use Disorder

Michael P. Frost, Sandra D. Comer, Michelle R. Lofwall, Sharon L. Walsh, Genie L. Bailey, Peter Almgren, Stefan Peterson, Elin Banke Nordbeck, Susanna Meyner, Adam Friedman*, Natalie R. Budilovsky-Kelley

Adam Friedman, Braeburn Inc, Plymouth Meeting, PA, USA

T3. NMDA-Receptor Partial Agonists as a Potential Approach to the Treatment of Ethanol Binge Drinking Behavior in a Mouse Model

Hannah Campbell*, Madeline Newlin, Caitlyn Magee, Cynthia Kuhn Hannah Campbell, Duke University

★T4. The Entactogen, EMP-01, Represents a Novel Approach to the Treatment of Social Anxiety Disorder with its Pharmacological Selectivity and Distinct Subjective Effects Supportive of Safety and Therapeutic Utility

Sarah McEwen*, Sarah McEwen, Carrie Bowen, Jonathon Holt, Holden Janssens, Glenn Short, Kevin Craig, Srinivas Rao

Sarah McEwen, atai Life Sciences



T5. A Placebo Controlled Trial of Cariprazine in Social Anxiety Disorder

Jason Careri*, Rita Hanover, Elizabeth Ducat, Jenny Wallier, Skylar Scull, Julie Newcombe, Nichika Holdrum, Matt Turzilli, Ann Draine, Michael Liebowitz Jason Careri, Medical Research Network

T6. Regulation of the Kynurenine Pathway Metabolism with the Galantamine-Memantine Combination in the Treatment of Autism Spectrum Disorders

Phillip Bempong*, Niyathi Vadlapalta, Aravind Menon, John Esposito, Maju Koola Phillip Bempong, New Jersey Medical School Department of Psychiatry

T7. Improving Test-Retest Reliability of EEG-Based Connectomics Using Individualized Structural MRI-Based Templates: Findings from Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) Nabila Haque, Russell Toll, Thomas Carmody, Manish Jha, Madhukar Trivedi, Amrita Ghose*

Amrita Ghose, The University of Texas Southwestern Medical Center, Department of Psychiatry

T8. Lithium Toxicity following Initiation of Semaglutide in a Patient with Bipolar 1 Disorder: A Case Report and Literature Review

Majd Al-Soleiti*, Jonathan Leung, Christopher Sola Majd Al-Soleiti, Mayo Clinic, Dept. Psychiatry and Psychology

T9. Cost-Effectiveness of Cariprazine Versus Aripiprazole in Patients with Bipolar I Disorder

Huiying Guo, Mousam Parikh, Robert Boer, Jamie Ta* Jamie Ta, AbbVie, North Chicago, IL, USA

T10. Healthcare Resource Utilization following Cariprazine Initiation Among Medicare Beneficiaries with Bipolar I Disorder

Mousam Parikh, Sally W. Wade, Nadia Nabulsi*, Andrea Barthel, Andrew Rava, Haiyan Sun, Lakshmi Kandukuri, Zheng Wu, Yajin Zhao, Tracy Yee, Thomas Wasser, Jamie Ta Nadia Nabulsi, AbbVie, North Chicago, IL, USA

T11. Real World Assessment of Health Care Resource Use for Manic Events among Patients Treated with Cariprazine or Other Atypical Antipsychotics for Bipolar I Disorder

Roger S. McIntyre, Mousam Parikh, Enrico Zanardo, François Laliberté, Huy-Binh Nguyen, Eric Christopher, Kaixin Zhang, Sophie Ma, Jamie Ta*, Lauren Aronin Jamie Ta, AbbVie, North Chicago, IL, USA

T12. Effective Treatment of Hypomania with the Use of Lurasidone in a Bipolar 2 Disorder Patient: A Case Report and a Review of the Literature

Majd Al-Soleiti, Jonathan Leung, John Powers, Abigail Tarasewicz* Abigail Tarasewicz, Mayo Clinic, Dept. Psychiatry and Psychology



T13. Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Bipolar I Disorder

Rakesh Jain, Hemangi Panchmatia*, Alejandro G. Hughes, Michael J. Doane, Hara E. Oyedeji, Andrew J. Cutler

Hemangi Panchmatia, Alkermes, Inc.

T14. Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Schizophrenia

Andrew J. Cutler, Hemangi Panchmatia*, Alejandro G. Hughes, Michael J. Doane, Hara E. Oyedeji, Rakesh Jain

Hemangi Panchmatia, Alkermes, Inc.

T15. Solriamfetol for Excessive Daytime Sleepiness in Patients with Narcolepsy and OSA Reporting Anxiety and Depression in the Real-World SURWEY Study

Ulf Kallweit, Heike Benes, Lothar Burghaus, Graham M.L. Eglit, Samantha Floam, Gregory Parks, Hasib Bhojwani*, Yaroslav Winter

Hasib Bhojwani, axsome therapeutics

T16. Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized-Withdrawal Double-Blind Placebo-Controlled Study

Jeffery Cummings, George Grossberg, Caroline Streicher, Courtney Zeni*, Herriot Tabuteau Courtney Zeni, Axsome Therapeutics Inc. New York, NY, USA

T17. Impact of Screening Call Duration on Initial Evaluation Attendance Rate for Alzheimer's Disease Drug Trials

Ralph Lee*, Yu-Jay Huoh, Brenda Martinez, Elizabeth Sosa, Tara Parnitvithikul, Elly Lee Ralph Lee, Irvine Clinical Research

T18. Does Treatment for Insomnia Improve Sleep State Misperception?

Dinesh Kumar, Jocelyn Y. Cheng, Margaret Moline* Margaret Moline, Eisai Inc.

T19. Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets

Sean Chadwick*, Rosarelis Torres, Changfu Xiao, Christos Polymeropoulos, Gunther Birznieks, Mihael Polymeropoulos

Sean Chadwick, Vanda Pharmaceuticals

T20. Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs

Beatrice Setnik*, Denise Milovan

Beatrice Setnik, Altasciences



T21. Navigating the Unchartered Territory of Assessing Psychedelics in Human Abuse Potential Studies

Beatrice Setnik*, Jadwiga Martynowicz, Anthony Coulson, John Carlos Diaz, Amir Inamdar, Shishuka Malhotra, Denise Milovan, Collin Price, Claire Roberts, Joyce Tsai, Berra Yazar-Klosinski

Beatrice Setnik, Altasciences

T22. Effects of SGLT2 Inhibitors on Lithium-Associated Kidney Dysfunction in Patients with Mood Disorders: A Historical Cohort Proof-Of-Concept Study

Mete Ercis, Idil Tarikogullari, Vanessa Pazdernik, Maria L Gonzalez Suarez, Raman Baweja, Osama A. Abulseoud, Jonathan Leung, Ashok Seshadri, Susan McElroy, Alfredo Cuellar-Barboza, Michael Gitlin, Aysegul Ozerdem, Mark A. Frye, Balwinder Singh* Balwinder Singh, Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN

T23. Evidence-Based Dosing of Brexpiprazole in Patients with Agitation Associated with Dementia Due to Alzheimer's Disease: An Exposure–Response Analysis

Christoph Correll, Yanlin Wang, Sanjeda Chumki, David Wang, Arash Raoufinia, Jogarao Gobburu, Pedro Such, Amita Patel*

Amita Patel, Joint Township District Memorial Hospital, St Mary's, OH, USA; Private Practice, Dayton, OH, USA

T24. Development of Deuterated Analogues of Psychedelics for the Treatment of Mental Health Conditions

Amir Inamdar*

Amir Inamdar, Cybin Inc

★T25. Targeting the KCNQ (a.k.a., Kv7) Potassium Channel as a Novel Treatment for Depression and anhedonia: Initial Results from a Randomized, Controlled Trial of XEN1101 vs. Placebo in Adults with Major Depressive Disorder

James Murrough*, Rachel Freemont, Jessica Ables, Philipp Neukam, Usha Govindarajulu, Helena Chang, Sara Hameed, Marcella Corwin, Mackenzie Hargrove, Laurel Morris, Sanjay Mathew

James Murrough, Icahn School of Medicine at Mount Sinai

T26. Reduced Depressive Symptoms After a Single Treatment with MM120 (Lysergide) in Patients with Generalized Anxiety Disorder Presenting with Comorbid Depressive Symptoms

Todd Solomon, PhD*, Paula L. Jacobsen, PhD, Sarah M. Karas, PsyD, Jamie M. Freedman, BS, Daniel R. Karlin, MD, MA

Todd Solomon, PhD, Mind Medicine Inc.

T27. Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects from Preclinical and Human Studies

Kristina Kumpf*, S. William Li, Julian Urrutia Ripoll, John Krystal, Gerard Sanacora, Samuel Wilkinson

Kristina Kumpf, Yale University, Child Study Center



T28. A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Thyromimetic ABX-002 in Healthy Adult Participants

Bridgette Franey*, Ashlee Heldreth, Heather Smith, Jason Everett, Alida Barry, Jason Harris, Jihao Zhou, Tom Scanlan, Jeffrey Vivian, Gudarz Davar Bridgette Franey, Autobahn Therapeutics

T29. Development of a Machine Learning Model for Estimating CGI-I Scores Using Electronic Medical Records from Real-World Data Sources

Stevan Severtson, Pedro Alves, Costas Boussios, Carl Marci* Carl Marci, OM1, Inc.

T30. Adjunctive Lumateperone in Patients with Major Depressive Disorder: Results from an Additional Randomized, Double-Blind, Phase 3 Trial

Willie Earley*, Suresh Durgam, Susan G. Kozauer, Yifan Mo, Hassan Lakkis, Renee Rotolo, Susan G. Kornstein, Maurizio Fava Willie Earley, Intra-Cellular Therapies, Inc.

T31. Characteristics of Akathisia with Long-Term Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses of a Phase 3 Open-Label Trial

Rakesh Jain, Jun Yu, Simranpreet Waraich* Simranpreet Waraich, AbbVie, North Chicago, IL, USA

T32. Psilocybin Therapy for Chronic Suicidal Ideation: An Open-Label Study

Andrew van der Vaart*, Audrey Shoultz, Bryce Lund, Tammy Miller, Jeffrey LaPratt, Scott Aaronson

Andrew van der Vaart, Sheppard Pratt Health System and University of Maryland School of Medicine

T33. Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder and Anxious Distress

Suresh Durgam*, Willie R Earley, Susan G Kozauer, Changzheng Chen, Dennis Sholler, Gary S. Sachs

Suresh Durgam, Intra-Cellular Therapies, Inc.

T34. Examining the Impact of Childhood Trauma on Ketamine's Real-World Effectiveness in Treatment-Resistant Depression

Danica Johnson*, Nelson Rodrigues, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat Danica Johnson, University of Toronto

T35. A Novel Artificial Intelligence-Based Methodology for Predicting Non-Specific Response to Treatment in Major Depressive Disorder Clinical Trials

Clotilde Guidetti*, Maurizio Fava, Paolo Manfredi, Marco Pappagallo, Roberto Gomeni Clotilde Guidetti, Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA



T36. Changes in Symptoms of Anhedonia with Psilocybin-Assisted Psychotherapy: A Secondary Analysis of a Randomized Clinical Trial for Treatment-Resistant Depression

Erica Kaczmarek*, Nelson Rodrigues, Noah Chisamore, Zoe Doyle, Shakila Meshkat, Marc G Blainey, Ryan Brudner, Shaun Ali, Kayla M Teopiz, Roger S McIntyre, Joshua D Rosenblat

Erica Kaczmarek, University of Toronto

★T37. Safety and Efficacy of GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized, Controlled Trial

Michael E. Thase*, Bernhard T. Baune, Narcís Cardoner, Rosa Maria Dueñas Herrero, Luboš Janů, John R. Kelly, Shane McInerney, Alexander Nawka, Tomáš Páleníček, Andreas Reif, Víctor Pérez Sola, Madhukar H. Trivedi, Velichka Valcheva, Eduard Vieta, Wiesław J. Cubała

Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC, Philadelphia, PA

T38. Safety and Tolerability of GH001 in Treatment-Resistant Depression: Results from a Phase 2b, Double-Blind, Randomized, Controlled Trial

Wiesław J. Cubała*, Bernhard T. Baune, Narcís Cardoner, Rosa Maria Dueñas Herrero, Luboš Janů, John R. Kelly, Shane J. McInerney, Alexander Nawka, Tomáš Páleníček, Andreas Reif, Victor Perez Sola, Madhukar H. Trivedi, Velichka Valcheva, Eduard Vieta, Michael E. Thase

Wiesław J. Cubała, Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

T39. Results of a Phase 2a Clinical Trial of Inhaled Mebufotenin (GH001) in Patients with Postpartum Depression

Claus Bo Svendsen*, Emilio Arbe, Sem E. Cohen, Kristina M. Deligiannidis, William Gann, Sarah Keady, Rachael MacIsaac, Stuart Ratcliffe, David R. Rubinow, Dan Tully, Velichka Valcheva, Jasper B. Zantvoord, Martin Johnson

Claus Bo Svendsen, GH Research, Dublin, Ireland

T40. A Circuit-Based Approach to Target Validation Using Optogenetics

Kimberly R Thompson*, Zane C Norville, Alice Shi On Hong, Susmita Chatterjee, James Lillie, Michael W Wood, Anatol C Kreitzer

Kimberly R Thompson, MapLight Therapeutics

T41. Non-Sulfonamide Dual Orexin Receptor Agonists: Preliminary Results of AEX-41 and AEX-2 in a Mouse Model of Narcolepsy

Leila Langbour, Sebastien Arthaud, Christelle Peyron, Anh-Tuan Lormier, Maxime Robin, Eric Konofal*

Eric Konofal, University of Paris, Robert-Debré Hospital, France



T42. Treatment Patterns for Sleep Disorders in the United States Veterans Affairs Health System

Karla Brandao-Viruet, Ying Wang*, Joel Reisman, Shibei Zhao, Brant Mittler, Dan Berlowitz, Peter Morin, Amir Abbas Tahami Monfared, Margaret Moline, Quanwu Zhang, Weiming Xia

Ying Wang, Wentworth Institute of Technology

T43. OPEN BOARD

T44. Speech-Based Quality Analysis in COA Administration: Profiling Clinician Behaviors in Madrs Interviews

Georgios Efstathiadis, Michelle Worthington, Anzar Abbas* Anzar Abbas, Brooklyn Health

T45. Personalized Accelerated Intermittent Theta Burst Stimulation for Post-Acute Suicidal Ideation: A Pilot Study Proposal

Se Ri Bae*, Manpreet Singh

Se Ri Bae, UC Davis Department of Psychiatry and Behavioral Sciences

T46. Examining Within-Person Longitudinal Change on a Mobile Verbal Learning Test in Adults with and Without HIV

Alena Stasenko, Laura M. Campbell, Anne Heaton, Jonathan L. Helm, David J. Moore, Robert K. Heaton, Colin A. Depp, Amy E. Pinkham, Robert A. Ackerman, Philip D. Harvey, Raeanne Moore*

Raeanne Moore, University of California San Diego

T47. Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment

Andrew J. Cutler, Laxman Bahroo, Kira Aldrich*, Elaine Liu, Cathy Zeng, Khody Farahmand

Kira Aldrich, Neurocrine Biosciences, Inc.

T48. Indirect Treatment Comparison of Somnolence or Sedation with Dopamine Partial Agonists Versus D2 Receptor Antagonists in Major Depressive Disorder and Schizophrenia

Nadia Nabulsi*, Jamie Ta, Filmon Haile, Mousam Parikh, Ning Cheng, Nahida Mirza, Kateryna Onishchenko, Nika Adham, Shane Varughese, Julie Adams Nadia Nabulsi, AbbVie, North Chicago, IL, USA

T49. Medication Adherence following Pharmacogenomic Testing in Insurance Claims Data from Patients with Major Depressive Disorder

Andria Del Tredici*, Holly Johnson, Brady DeHart, Alexander Gutin, Katie Johansen Taber, Pamela Morin, Laura Becker, Julia Certa, Boadie Dunlop, Devika Chawla, Andrew Nierenberg

Andria Del Tredici, Myriad Genetics



T50. Comparison of Pharmacological Management in the Treatment of Perinatal Depression: Efficacy, Tolerability, Teratogenicity, and Ethical Considerations

Abdul Khan*, Saba Saleem, Mohammad Memon, Faisal Suba, Mujeeb Shad Abdul Khan, Valley Health System

T51. Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study

Jacob Ballon*, Christina Arevalo, Martin Dunbar, Alexandra Lovett, David McDonnell, Christoph U. Correll

Jacob Ballon, Stanford University

T52. What's in a Word: Can Discourse Analysis of the Linguistic Choices Made by Patients Provide Clinicians with Deeper Insights into Patients' Perspectives?

John Adeniji, Anyinke Atabong, Craig Chepke, Michael Ingram, Amber Hoberg, Shalina Omar, Maurcio Tohen, Joseph Goldberg*

Joseph Goldberg, Icahn School of Medicine at Mount Sinai

T53. Black Adults who Stopped Engaging in Care Prior to Firearm Suicide Death: A Preliminary Analysis of National Violent Death Reporting System Data, 2013-2021

Evan Goldstein*, Aryanna Sanger

Evan Goldstein, University of Utah School of Medicine

T54. Effect of Dose on Xanomeline and Trospium Chloride Efficacy and Safety: Post Hoc Analysis of Data from the Three 5-Week Emergent Trials

Inder Kaul, Soumya A Charturvedi, Tejendra R Patel, Nichole Neugebauer, Eliesha Daniels*, Pierre Nicolas, Amy Claxton

Eliesha Daniels, Bristol-Myers Squibb

T55. Pooled Analysis of Extrapyramidal Symptoms in Adults with Schizophrenia in the Long-Term, Open-Label Trials of Xanomeline and Trospium Chloride

Inder Kaul, Tejendra R Patel, Soumya A Charturvedi, Wei-Chih Lin, Amy Claxton* Amy Claxton, Bristol-Myers Squibb

T56. Treatment Effects of Olanzapine/Samidorphan on Negative Symptoms in Patients with Schizophrenia: A Post Hoc Analysis

Roger S. McIntyre, Desiree M. Matthews, Marni Harris, Christina Arevalo*, Martin Dunbar, David McDonnell, Christoph U. Correll

Christina Arevalo, Alkermes, Inc., Waltham, MA

T57. Study Retention Rates in the Olanzapine/Samidorphan Phase 3 Clinical Program

René S. Kahn, Christina Arevalo*, Marni Harris, David McDonnell Christina Arevalo, Alkermes, Inc., Waltham, MA

T58. Baseline Severity of Illness and Response to Treatment with Aripiprazole Lauroxil Every 2 Months: A Post Hoc Analysis of Phase 3 ALPINE Clinical Trial Data

John Kane*, Martin Dunbar, James A. McGrory

John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell



T59. OPEN BOARD

T60. Combined Ketamine and Dialectical Behavioural Therapy for Suicidality in Comorbid Treatment-Resistant Depression and Borderline Personality Disorder: A Phase II Randomized, Midazolam-Controlled Clinical Trial Protocol

Orly Lipsitz*, Shelley McMain, Amer Burhan, Joshua D Rosenblat Orly Lipsitz, University of Toronto

T61. A Theoretical Exploration of the Effect of Psilocybin on Insight from a Neurobiological Perspective and Its Clinical Implications

Misbah Alam*, Mustafa Alam, Mujeeb Shad Misbah Alam, The Valley Health System

T62. Maternal Mental Health Outcome After Stillbirth Deliveries: A Secondary Analysis Study

Rana Jawish*, Rana Jawish, Robert Silver, Mark Rapaport Rana Jawish, University of Utah School of Medicine

T63. Zuranolone for Postpartum Depression: What is the Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed?

Leslie Citrome*, Derek Louie, Boyang Bian, Xiaotong Jiang, Theresa M. Vera, Veronica Nguyen, Melanie Young

Leslie Citrome, New York Medical College

★T64. TSND-201 (Methylone) as a Treatment for PTSD: Rapid, Robust and Long-Lasting Activity in Phase 2

Jennifer Warner-Schmidt*, Amanda Jones, Martin Stogniew, Blake Mandell, Benjamin Kelmendi

Jennifer Warner-Schmidt, Transcend Therapeutics

★T65. Development of GATE-251, an Orally Bioavailable Positive Allosteric Modulator of the NMDA Receptor, to Treat Major Depressive Disorder in Subjects with Comorbid Insomnia and Anxiety

Anantha Shekhar*, Ronald Burch, John Donello Anantha Shekhar, University of Pittsburgh

T66. Expanded Analysis of MM120 (Lysergide) for Generalized Anxiety Disorder: Updated Findings on Quality of Life and Depressive Symptoms

Daniel Karlin, MD, MA*, Todd M. Solomon, PhD, Paula L. Jacobsen, PhD, Sarah M. Karas, PsyD, Jamie M. Freedman, BS

Daniel Karlin, MD, MA, Mind Medicine Inc., Department of Psychiatry, Tufts University School of Medicine



T67. Development and Cognitive Debriefing of the Anhedonia Interview Rating Scale Clinician (AIRS) and Self-Report Version (AIRS-SR)

Jenicka Engler*, Chris Kelly, Miriam Evans, Dyanna Domilici, Marian Acquino, Sean Madden, Cynthia McNamara, Janet Williams, James Murrough Jenicka Engler, Cronos, an IOVIA Business

T68. Robust Antidepressant Efficacy of the Novel 5-HT2A Receptor Agonist GM-2505 in a Double-Blind, Randomized, Controlled Phase 2a Trial in Patients with MDD

Gerard Marek*, Daniel Umbricht, Edward Christian, Jason Winters, Shane Raines, William Leong, Laszlo Kiss, Zoe Hughes, Robert Berman, Jorge Quiroz, Andrew Kruegel, Jonathan Sporn

Gerard Marek, Gilgamesh Pharmaceuticals, Inc.

T69. Evaluating the Association Between Antidepressant Efficacy and Dissociation with Ketamine in Treatment-Resistant Bipolar Depression (TRBD)

Sara Di Luch*, Diana Orsini, Tayyeba Shaikh, Rodrigo Mansur, Roger McIntyre, Joshua Rosenblat

Sara Di Luch, University Health Network

T70. Predicting Difficult-To-Treat Depression Before It Becomes Treatment Resistant

Mark Zimmerman*, Daniel Mackin

Mark Zimmerman, Brown University

T71. Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example

Mark Zimmerman*, Matthew Snyder

Mark Zimmerman, Brown University

T72. Converging pathways: Shared Brain Activity Engaged by Monoaminergic antidepressants, Ketamine and Psilocybin

Pavel Osten*, Kadeem Joseph, Janelle Collins, Thomas Genovese, Myran Maxwel, Jeffrey Lieberman

Pavel Osten, Theracast

T73. Antidepressant Itruvone Nasal Spray Depolarizes Nasal Chemosensory Receptors Followed by Increased Gamma Power Spectral Density of the Olfactory Bulb in Healthy Subjects

Louis Monti*, Danajane Katz, Ester Salmán, Weiping Zhang, Ross Baker, Rita Hanover, Louis Monti, VistaGen Therapeutics, Inc.

T74. Prescriber and Patient-Level Characteristics Associated with Adherence to Antipsychotics among Patients with Schizophrenia in the United States

Arthur Voegel, Charmi Patel, Lilian Diaz, Claire Vanden Eynde, Yuxi Wang, Ronaldo R Naranjo Jr, Dominic Pilon, Carmela Benson*, Leslie Citrome Carmela Benson, Johnson and Johnson, Titusville, NJ



T75. An Open-Label Study of Single-Dose COMP360 Psilocybin for Post-Traumatic Stress Disorder: Safety, Tolerability, and Secondary Efficacy Outcomes

Niall McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Hollie Simmons, Shriya Das, Guy Goodwin*

Guy Goodwin, Compass Pathfinder Ltd. (a subsidiary of Compass Pathways plc), London, UK

T76. Effect of Long-Term Treatment with Adjunctive Cariprazine on Anhedonia in Patients with Major Depressive disorder: Post Hoc Analysis of a 26-Week Open-Label Study

Andrew J. Cutler, Craig Chepke, Andrea C. Wilson, Jun Yu, Ajarvis Cobb*, Simranpreet Waraich

Ajarvis Cobb, AbbVie

T77. Study Design of BALANCE-AAD-1, a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the FAAH/MAGL Inhibitor BMS-986368 for Treatment of Agitation in Patients with Alzheimer Disease

Walter Heine*, Rachel Heimall, Rosa Miceli, Brielle Carramusa, Yue Zhang, Rui Zhao, Jennifer Reardon, Richard Leigh-Pemberton

Walter Heine, Bristol Myers Squibb, Princeton, New Jersey

T78. Revisiting Long-Term Lithium Therapy and Chronic Kidney Disease in Bipolar Disorder: An Updated Cohort Study

Idil Tarikogullari*, Mete Ercis, Vanessa Pazdernik, Maria L Gonzalez Suarez, Marin Veldic, Katherine Moore, Hannah Betcher, Osama A. Abulseoud, Aysegul Ozerdem, Alfredo Cuellar-Barboza, Francisco Romo-Nava, Susan McElroy, Joanna Biernacka, Mark Frye, Balwinder Singh

Idil Tarikogullari, Mayo Clinic, Dept. Psychiatry and Psychology

T79. Improvement to Quality of Life and Depression Show Independent Pathways in Psilocybin Response

Audrey Shoultz*, Andrew Van der Vaart, Scott Aaronson Audrey Shoultz, Sheppard Pratt Health System

T80. Long-Term Safety and Tolerability of Xanomeline and Trospium Chloride: Pooled Results from the 52-Week, Open-Label EMERGENT-4 and EMERGENT-5 Trials

Inder Kaul, Stephen K. Brannan, Sharon Sawchak, Tejendra R Patel, Soumya Chaturvedi*, Ayesha Pavithran, Amy Claxton

Soumya Chaturvedi, Bristol-Myers Squibb

T81. Results from the Phase 3, Double-Blind, Placebo-Controlled VENTURA-1 and -2 Studies of Aticaprant, Adjunctive to Antidepressants, in Adults with Major Depressive Disorder with Moderate-To-Severe Anhedonia

Vanina Popova*, Maha Ahmad, Alexandre Lemle, Naim Zaki, Filip Delaei, Li Nancy Chen, Xin Qiu, Rama Melkote, Michael E. Thase, Richard C. Shelton, Maurizio Fava, Andrew D. Krystal, Magali Arons, Carla M. Canuso, Wayne C. Drevets

Vanina Popova, Johnson and Johnson, Beerse, Belgium



T82. Results from Early-Stage Trials of Inhaled Mebufotenin (GH001) in Healthy Volunteers and Patients with Treatment-Resistant Depression

Kelly Doolin*, Velichka Valcheva, Claus Bo Svendsen, Padraig O'Grady, Michael E. Thase, Johannes T. Reckweg, Johannes G. Ramaekers Kelly Doolin, GH Research, Dublin, Ireland

T83. Population-Level Changes in Substance Use Trends Based on Criminal Justice System Involvement: Findings from the 2023 National Survey on Drug Use and Health

Shruti Patil*, Manish Jha, Abu Minhajuddin

Shruti Patil, University of Texas Southwestern Medical Center

T84. Do Central Raters Remain Blinded in a Large Psychedelic Clinical Trial?

Javier Muniz, MD*, Sarah M. Karas, PsyD, Adam Kolar, PhD, Todd M. Solomon, PhD, Daniel R. Karlin, MD, MA

Javier Muniz, MD, Mind Medicine Inc.

T85. Ropanicant (SUVN-911), an $\alpha 4\beta 2$ nAChR antagonist: Outcome of a Phase-2a Clinical Trial Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder

Ramakrishna Nirogi, Abdul Rasheed Mohammed, Veera Raghava Chowdary Palacharla*, VIjay Benade, Jyothsna Ravula, Satish Jetta, Vinod Kumar Goyal, Ramkumar Subramanian, Santosh Kumar Pandey, Pradeep Jayarajan, Anil Shinde

Veera Raghava Chowdary Palacharla, Suven Life Sciences

T86. Pharmacokinetic and Safety Comparison of MM120 (Lysergide) Capsules and Orally Disintegrating Tablets in Healthy Adults

Ezekiel Powdar, MS, Nithya Srinivas, PhD, Todd M. Solomon, PhD, Sarah Karas*, Jamileh Jemison, MD, MA, Amy Engel, MS, Daniel R. Karlin, MD, MA Sarah Karas, Mind Medicine (MindMed), Inc

